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Klebsiella pneumoniae (KP) is a significant paediatric bloodstream pathogen in 
children. There is little data about KP in South African children. The focus for the 
present study was to address this knowledge gap. 
Methods: This study addressed a retrospective case notes review on bloodstream 
Klebsiella pneumoniae infections at a children’s hospital in Cape Town, South Africa 
2006-2011 using conventional descriptive and comparative statistical methods.  
Results: Of 410 hospitalised children with laboratory confirmed KP bloodstream 
infection (KPBSI), 339 (83%) were caused by presumed extended-spectrum β-
lactamase (ESBL) producing isolates. The median age (interquartile range, IQR) was 
5.0 (2-16) months, 212 (51.7%) were male, 82 (20%) were HIV-infected, and 241 
(58.8%) were moderately or severely underweight. The infection was nosocomial or 
healthcare-associated in 389 (95%) children and community-acquired in 21 (5%) 
children. Significant risk factors for the acquisition of ESBL-KP bloodstream infection 
included cephalosporin exposure in the preceding 12 months prior to the KPBSI 
p=<0.0001: aRR 1.27 (95% CI: 1.15-1.40); HIV infection p=0.01: aRR 1.12 (1.02-
1.22), and those who had intravenous infusions for more than 3 days prior to the 
KPBSI, p=0.002: aRR 1.21(95% CI: 1.07-1.36). 
The median age of 123 (30%) children who died was four (IQR 1-15) months. The 
median, IQR, time between KPBSI and death was four (IQR 1-13) days. Patients with 
significant risk factors for death included those having HIV-infection, p=<0.0001: 
aRR 1.8(95% CI: 1.32-2.45); having excoriated skin, p=<0.0001: aRR 1.74 (95% CI: 
1.31-2.32); being in PICU, p= 0.01: aRR 1.61 (95% CI: 1.13-2.30) or needing PICU 
admission, p= 0.004: aRR 1.7 (95% CI: 1.18-2.45). 
Conclusion: ESBL-producing KP is an important cause of laboratory confirmed 
bloodstream infection at this children’s hospital and is associated with high 
mortality. Improved infection control practice and antibiotic stewardship are 
essential for controlling this pathogen. 
Key words: Klebsiella pneumoniae bloodstream infection, children, Africa 
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CHAPTER ONE: INTRODUCTION 
1.1 The problem of Klebsiella pneumoniae: 
Klebsiella pneumoniae (KP) are Gram-negative bacteria from the Enterobacteriaceae 
family. This large family includes the genera Citrobacter, Enterobacter, Escherichia, 
Klebsiella, Morganella, Proteus, Providencia, Salmonella, Serratia, Shigella, and 
Yersinia. These bacteria are all facultative anaerobes that are oxidase negative; they 
also share the ability to ferment glucose, reduce nitrates to nitrites, and most are 
motile.  
Klebsiella species are found in two main places: in natural environmental habitats like 
soil, surface water collections, and sewage and on mammalian mucosal surfaces. 
Three major species of Klebsiella are of clinical relevance: KP, oxytoca, and 
rhinoscleromatis. KP are by far the most commonly isolated species and the most 
clinically important; they colonise mainly the upper respiratory tract and extensively 
inhabit the colon. They have tenacious mucoid polysaccharide capsules that protect 
them against phagocytosis and antibiotic destruction while contributing to their 
cytotoxic effect. Early literature often used the name Bacillus mucosus capsulitis, 
somewhat depicting these properties (Bensley, 1932). KP belong to the group of 
biofilm-associated organisms. Biofilm formation has been described in patients with 
any foreign indwelling medical devices. Indwelling vascular catheters, endotracheal 
tubes, and urinary catheters are particularly associated with KP biofilm formation. 
Biofilm provides protection for the adhering microorganisms against the host’s 
immune system, antibiotic penetration, and a medium in which to exchange 
resistance plasmids (Donian, 2001); as such the biofilm nidus provides an ever-
present risk for invasive nosocomial infections. Studies have shown the presence of 
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fimbriae in all KP isolates to mediate adherence to indwelling device surfaces (Schroll 
et al., 2010). Unlike the other Enterobacteriaceae, they are non-motile. 
Under antibiotic selection pressure, KP acquire and produce a variety of beta (β)-
lactamase enzymes that confer antibiotic resistance mainly by hydrolysing the β-
lactam rings of antibiotics. Extended-spectrum beta-lactamases (ESBLs) are a 
particular type of plasmid-encoded beta-lactamase enzyme. This enzyme is able to 
hydrolyse a wide spectrum of β-lactam antibiotics including 3rd and 4th generation 
cephalosporins.  
ESBL genes may be located on bacterial chromosomes but are primarily located on 
plasmids through which they can be transferred between Gram-negative bacteria by 
translocation. Examples of extended-spectrum beta-lactamases include TEM, SHV, 
and CTX-M each of which is associated with sub-variants differing in expression only 
by regional location. Researchers have described over 1000 variants (Malloy and 
Campos, 2011). Any given organism may express more than one type of ESBL. These 
multidrug resistant organisms may disseminate within and between wards and 
hospitals, ultimately becoming a global problem.  
Findings of patients and retail poultry meat with the same ESBL plasmids, genes, and 
strains provided some evidence of horizontal transmission from animals to humans. 
This horizontal transmission is most likely via the food chain. Researchers thought 
there was a link between this phenomenon and high antibiotic use in the poultry 
industry (Mesa et al., 2006). Other areas of animal husbandry also make extensive use 
of antibiotics. Antibiotic selection pressure for resistance and plasmid dissemination 
drives the spread of resistance.  
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Colonised patients serve as an infection reservoir in humans. In one study, 
researchers showed that up to 75% of patients remain colonised with ESBL-
producing organisms for at least 2 months and that colonisation lasted for more than 
1 year in up to 25% of patients (Leverstein-van Hall and Muilwijk, 2010). In another 
study, the median duration of faecal carriage in 51 infants discharged from a neonatal 
intensive care unit was 12.5 (IQR 9-17.5) months, with the longest time of 23.5 
months in one infant. Furthermore, it appeared that the colonised infants transmitted 
the CTX-M-15 KP isolate to 20% of other household members. Thus, this magnified 
the serious concerns on the ease of dissemination and colonisation by resistant KP 
(Löhr et al., 2013). 
KP bacteria may cause serious multi-organ disease that is associated with high 
mortality. The spectrum of clinical infectious manifestations caused by KP bacteria 
include: 
 pneumonia  
 urinary tract infections (UTI) 
 biliary tract infection 
 wound and soft tissue infection 
 abscess formation 
 bone infection 
 meningitis 
 diarrhoeal disease 
 necrotising enterocolitis (NEC)  
 bloodstream infections (BSI) 
 4  
Early signs of a BSI, whether nosocomial or community acquired, include fever, 
tachycardia, tachypnoea, and general malaise. In neonates, early signs include apnoea, 
temperature instability, skin mottling, convulsions, drowsiness, irritability, poor 
feeding, and feed intolerance may be other more subtle manifestations (WHO, 2005). 
Uncontrolled sepsis can escalate to septic shock and multi-organ failure in a short 
period. 
1.2  Literature search 
A MEDLINE/ Pubmed database search was conducted from 1966 to December 
2011 for English language studies of humans for articles that reported KP BSI in 
children from birth to 18years of age.  The search terms included:  
- (child or children or  infant or adolescent) AND 
-  (paediatrics or paediatrics; paediatric or pediatric) AND 
-  (sepsis or septicaemia or septicaemia) AND 
- (bacteraemia or bacteremia or blood circulation or bloodstream or 
bloodstream infection or bloodstream infections) AND 
- (Klebsiella or Klebsiella pneumoniae) AND 
- (extended spectrum beta lactamase or ESBL) AND 
- (risk factors) 
Four hundred and eighty five titles and abstracts of citations identified from the 
literature search were screened for relevance on paediatric KP bloodstream 
infections; case reports with <20 subjects, study groups including adults, children 
with mixed infections, studies exclusively involving neonates and preterm infants 
were excluded. Nineteen studies were deemed relevant. Additional searches were 
done on the reference sections of relevant studies. 
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1.3 Klebsiella pneumoniae bloodstream infections – the global 
picture 
One of the inevitable consequences of antibiotic use has been the microorganisms’ 
survival strategy through varying degrees of antimicrobial resistance (Datta and 
Hughs, 1983). Moreover, beta-lactamases were evident even before antibiotics were 
introduced into clinical use. The first documentation of plasmid transfer of 
cephalosporin antimicrobial resistance from nosocomial KP strains to E Coli was in 
Germany in 1983, over 30 years ago. In laboratory-based experiments, researchers 
were able to demonstrate conclusively the transfer of resistance plasmids between 
Gram-negative species from isolates taken from patients attending an outpatient 
clinic. Three serologically different clones of KP, resistant to cefotaxime, cefuroxime, 
and gentamicin but sensitive to cefoxitin, were readily transmissible to E Coli 
recipient strains after cultivating the carefully mixed incubated broth donor and 
recipient cultures and then re-evaluating the strains and their sensitivity patterns 
(Knothe et al., 1983).  
Thus, it appeared that the introduction of the powerful 3rd-generation cephalosporins 
into clinical use in 1981, in the US and South Africa, played a fundamental role in the 
evolution of the extended-spectrum beta-lactamases (ESBLs). Soon after, many more 
reports emerged, initially in the adult literature. It soon became clear that hospitalised 
children across the globe have not been immune to this problem (Aiken et al., 2011; 
Al-Zamil, 2008; Arnoni et al., 2007; Blaschke et al., 2009; Blomberg et al., 2005; Jaspan 
et al., 2008; Kim et al., 2002; Marra et al., 2006; Moyo et al., 2010; Pérez-González et 
al., 2007; Qin et al., 2008; Raymond et al., 2007; Singhi et al., 2008; Woerther et al., 
2011; Zaoutis et al., 2005). 
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As more antibiotics were introduced into the armamentarium against bacteria, so too 
did ß-lactamase combinations become more complex and diverse. Researchers first 
reported plasmid-mediated ESBL resistance to quinolone antibiotics conferring 
broad-spectrum resistance to hospital isolates of KP and E Coli in 1998. This provided 
evidence of the spread of quinolone-resistant mutants between Enterobacteriaceae 
(Martínez-Martínez at al., 1998).  
Not only is the problem a global one but a new threat has emerged with the 
carbapenemase-producing KP. This is a bacterial response to the more liberal use of 
carbapenem antibiotics as well as the continued abuse of all major antibiotic classes 
in both adult and paediatric populations. This review does not include KP 
carbapenamase resistance mainly because it emerged as a clinical problem at Red 
Cross War Memorial Children’s Hospital (RCWMCH) in 2012 and therefore falls 
outside the study period. However, researchers first reported KP carbapenamase 
resistance in South Africa in private hospitals in 2011, and it is likely to become a 
formidable clinical problem (see Table 1.1) (Brink et al., 2012).  
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Table 1.1: Key milestones in the development of antibiotic resistance in 
Enterobacteriaceae, with particular reference to Klebsiella pneumoniae 
(KP)  
Date of first clinical 
use of selected 
antibiotics 
Resistance documentation 









lactamase)-producing E Coli 
Abraham and Chain, 1940 
 
 1963 










ESBL- KP resistance 
plasmids 





KP Carbapenemase gene 






KP Quinolone resistance 
Martínez-Martínez et al., 
1998  
KP: Klebsiella pneumoniae 
E Coli: Escherichia Coli 
ESBL: extended-spectrum beta-lactamase 
TEM-1: the first described and most widespread beta-lactamase (resistance only to penicillin and 
ampicillin) 
 
A systematic review of 16 studies involving 215 bloodstream or lung isolates from 
children younger than 5 years with pneumonia in developing countries showed high 
risk of death in malnourished children with pneumonia. Researchers conducted ten 
of these studies in Sub-Saharan Africa and Asia. Within the studies, there were 
1062/4487 moderately malnourished children and 1866/11 497 severely 
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malnourished children. Their relative risk for mortality ranged from 1.2 to 36.5 for 
moderately malnourished children and 2.9 to 121.2 for severely malnourished 
children with pneumonia in comparison to children without. In severely 
malnourished children, KP and Staphylococcus aureus (MSSA) were the top two 
bacterial isolates implicated in the aetiology of the pneumonia in 26% and 25% of 215 
isolates from all studies that described the spectrum of pathogens. Streptococcus 
pneumoniae (18%), Escherichia coli (8%), Haemophilus influenzae (8%), and 
Salmonella spp. (5%) were the next most commonly isolated organisms. Researchers 
did not evaluate the contribution of these individual pathogens to mortality (Chisti et 
al., 2009).  
In the U.K., recent voluntary laboratory surveillance data on bacteraemia of selected 
Enterobacteriaceae from England, Wales, and Northern Ireland show that KP was the 
most common Klebsiella spp. The rate of laboratory-confirmed Klebsiella spp. 
infections  per 100 000 population had increased from 10.8 to 11.3 over 2008-2012, 
whilst infection rates due to the other reported Enterobacteriaceae, Enterobacter spp., 
Serratia spp. and Citrobacter spp., had declined slightly. Though numbers were small, 
KP BSI was higher in two groups: among infants and among the elderly. The annual 
proportion of all Enterobacteriaceae BSI reported in this laboratory surveillance due 
to KP had increased from 40.3 % (4 162/10 318) to 50.7% (5 105/10 066) over the 
5-year period. Antibiotic susceptibility testing showed resistance to 3rd-generation 
cephalosporins remained steady at about 10%, likely ESBL-related, over the 5 years. 
Resistance to the carbapenems was not common, and researchers first observed this 
in 2009. This study did not link clinical data to the laboratory isolates; therefore, 
clinical information of patients from whom the enterobacteriaceae were isolated, was 
not described (Public Health England, 2013). 
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1.4 Klebsiella pneumoniae bloodstream infections in African 
children 
Not much published information exists on the extent and effect of KP in paediatric 
BSIs in Africa. A summary of the few reports that exist follows: 
 A meta-analysis of community acquired BSIs in African adults and children found 
that KP is in fact not a common community-acquired bloodstream pathogen. 
Gram-negative organisms caused 54% of all the paediatric BSI from 22 studies 
conducted between 1984 and 2006. Enterobacteriaceae caused 36.8% of blood 
culture isolates, with Salmonella spp. being the most common genus in 21.4% of 
cases followed by non-salmonella Enterobacteriaceae in 15.3%; E Coli and KP spp. 
caused 9.4% and 2.8% of cases, respectively. This analysis showed that Gram-
positive infections caused 43.4% of all BSIs; other organisms caused the 
remaining 2.6% of BSI. Researchers tested 6% of the 43 130 study children for 
HIV infections. Of those tested, the prevalence of HIV infection was 18.5% (Reddy 
et al., 2010). There were no South African studies in the analysis. Non-typhoid 
salmonella (NTS) is a common cause of Gram-negative BSI in many African 
countries to the north of South Africa (Feasey et al., 2001).  
 In a Kenyan study, Klebsiella spp. ranked 9th out of 10 causes of bacterial isolates 
from 1094 paediatric Kenyan patients with bacteraemia (Berkley et al., 2005).  
 African reports are scarce with respect to antemortem BSIs. In a 7-year 
prospective study involving more than 26 000 Kenyan children, researchers 
described KP as the second most common Gram-negative organism that 
accounted for 20% of healthcare associated infections. The most common Gram-
negative organism was E coli while S aureus the most common Gram-positive 
pathogen, they accounted for 21% each, of all health-care associated infections. In 
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this study, researchers identified malnutrition and receipt of a blood transfusion 
as risk factors for healthcare-associated BSIs (Aiken et al., 2011).  
 Researchers described outbreak reports of KP septicaemia in neonatal and 
paediatric units throughout Africa including Nigeria and Tanzania, associating 
these with high mortality (Iregbu and Anwaal, 2007; Blomberg et al., 2005). This 
link with hospitalisation is an important pointer to the epidemiology of KP BSI in 
children. 
1.5 South African experiences of Klebsiella pneumoniae bloodstream 
infections in children 
One of the first paediatric studies documenting the role of KP in childhood infection 
in South Africa showed that KP was one of the dominant organisms causing healthcare 
associated BSIs in malnourished children in Johannesburg (Berkowitz, 1984). In this 
12-month prospective study conducted in 1982 at Chris Hani Baragwanath Hospital, 
a public hospital, researchers analysed community- and hospital-acquired BSI in 
children admitted to the general paediatric wards. Of 5397 admissions to the general 
paediatric wards, there were 337 significant bacterial bloodstream isolates from 315 
children. The mean age was 19 months, and 64 (20%) children had a chronic 
underlying medical condition.  
Over the study period, Streptococcus pneumoniae and Salmonella enteritidis were the 
most common organisms associated with community acquired pneumonia and 
gastroenteritis respectively, the first peaking in winter and the second peaking in 
summer. Nine of 22 (40.9%) were KP isolates, 3/8 (37.5%) were Pseudomonas 
aeruginosa isolates, and 7/21 (33.3%) were Staphylococcus aureus isolates causing 
nosocomial BSI in the study population. Susceptibility testing showed that 71% of the 
KP and 98% of the E Coli isolates were sensitive to Gentamicin. Researchers did not 
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report further sensitivity data for these organisms. In the patients with bacteraemia, 
the overall case fatality rate (CFR) was 23%; the CFR associated with KP BSI was 
higher at 32%. At this time, researchers did not test the children for HIV infection (see 
Table 1.2).  
Table 1.2: Ranking of the top 6 bloodstream pathogens by case fatality rate 
in hospitalised children (Berkowitz, 1984) 
Organism Case Fatality Rate 
Pseudomonas auruginosa 63 
Escherichia Coli 33 
Klebsiella pneumoniae 32 
Haemophilus influenzae 23 
Streptococcus pneumoniae 22 
Salmonella enteritidis 20 
 
Later, in 1989, another group of researchers described KP as one of the most common 
causes of nosocomial lower respiratory tract infections in hospitalised South African 
children in a study evaluating bloodstream pathogens. During the study period 8524 
children were admitted to the paediatric wards at Tygerberg Hospital, a large public 
hospital. Researchers documented 171 cases of bacteraemia in 165 patients: 77.2% 
(n=132) and 22.8% (n=39) were community and hospital-acquired respectively. The 
mean age of the children with BSI was 2.4 years. The most common community-
acquired bloodstream pathogens were Streptococcus pneumoniae (33% of cases), 
Staphylococcus aureus (13.6%), and Neisseria meningitidis (11.4%). Common 
hospital-acquired pathogens were Klebsiella spp. (18%) followed by Salmonella spp. 
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(13.4%). These Gram-negative BSIs occurred more commonly in malnourished 
children and in children with acute respiratory infections (Cotton et al., 1992).  
The role of HIV infection in South African paediatric BSI was unknown at that time 
though unlikely to be significant. The first documented cases of HIV infection in South 
Africa was in 1983 (Ras et al., 1983). 
The introduction of 3rd generation cephalosporin cefotaxime into the country to treat 
bacterial meningitis in 1981 may have contributed to the evolution of resistant KP. 
Although, this is unlikely to be the only explanation. Exposure to any antibiotic may 
induce bacterial resistance by imposing selective pressure.  
In 1990, a Cape Town-based, 4-year survey found that children hospitalised with 
measles were six times more likely to develop a nosocomial BSI compared with other 
children in the general paediatric wards (OR 6.1; 95% CI 3.2-11.8). KP and Salmonella 
were the most likely Gram-negative organisms in 47/64 (73.4%) Gram-negative 
isolates, and 22 (29.7%) were due to KP. Researchers postulated that measles-
induced immunosuppression was a major predisposing factor. The antibiotic 
resistance patterns at that time showed that although all the KP isolates were 
sensitive to cefotaxime and amikacin, 14/22 isolates were resistant to Gentamicin and 
chloramphenicol (Hussey and Simpson, 1990).  
A public sector South African surveillance study was completed on susceptibility 
testing on bloodstream pathogens from mixed adult and paediatric patients using 
hospital and community acquired infections in 2010. These researchers drew isolates 
from a number of participating public sector laboratories in Johannesburg, Cape 
Town, Pretoria, and Bloemfontein. The data documented high levels of antibiotic 
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resistance among KP isolates. In particular, between 55 and 74% of the KP isolates 
were classified as ESBL- producers (see Table 1.3) (Bamford et al., 2011).  
Table 1.3: Susceptibility testing for Klebsiella pneumoniae from the 2010 
Antimicrobial susceptibility Surveillance Data (Bamford et al): 







# extended-spectrum β-lactamase-producing Klebsiella pneumoniae inferred if 
the isolate was resistant to cefepime 
 
South African National surveillance data over 2 years showed increasing reports of 
resistance to carbapenem antibiotics from different public institutions (see Table 1.4) 
(Perovic et al., 2013). Although the percentage changes were small, the absolute 
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During a 2-year review, 2002-2003, at the neonatal unit at Chris Hani Baragwaneth 
Hospital in Johannesburg, a central referral centre in Gauteng, reviewers found 100 
neonates with ESBL-KP BSI and or ESBL-KP meningitis. From the available data on 
blood cultures taken at 48 hours after commencing the empiric combination therapy 
of piptazobactam and amikacin, about 47% (9/19) of isolates were resistant to this 
combination, necessitating a change to meropenem. Low birth weight (LBW) infants 
with KP BSI and meningitis had a high (30%) mortality rate, particularly if the illness 
involved respiratory failure and inadequate empiric therapy. The authors concluded 
by recommending carbapenem antibiotics for the treatment of all invasive ESBL-KP 
infections (Velaphi et al., 2012). 
In 2009, a 1-year review of BSIs at the neonatal unit at Charlotte Maxeke 
Johannesburg Academic Hospital in Gauteng revealed 246 BSIs in 181 infants. 
Researchers found KP, the second most common isolate after Staphylococcus 
epidermidis, to cause high mortality (29%) in infants. Of the KP isolates, 65% were 
ESBL-producers. Whilst all the E Coli isolates were sensitive to 3rd generation 
cephalosporins and aminoglycosides, 94% and 83% of KP isolates were susceptible 
to amikacin and ciprofloxacin respectively. Mortality was significantly higher in 
neonates with gram-negative infections 32/111 (28.8%) compared to those with 
gram-positive infections 14/135 (10.4%) (P < 0.001) (Ballot et al., 2012). 
1.6 Klebsiella pneumoniae infections in the study setting: Red Cross 
War Memorial Children’s Hospital 
Since 2011, KP has become the dominant nosocomial bacteraemic agent at RCWMCH 
(Lochan et al., 2013). RCWMCH is a multidisciplinary tertiary hospital dealing with 
not only children with complex medical conditions but also admitting children with 
diseases of poverty into in the level 2/3 functional area of the hospital. Poverty 
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diseases include malnutrition, diarrhoeal disease, respiratory infections, and 
tuberculosis. 
Researchers conducting a study reporting on the bloodstream pathogens at the 
institution over 5 years, from 2008 to 2012, found that Gram-negative organisms 
made up 57.9% (1679/2969) of isolates. KP was the most common 
Enterobacteriaceae and its prevalence showed significant reduction over the 5 years 
from 45.8% in 2008 to 31.7% in 2012 (Lochan et al., 2013).  
Researchers recently described KP as the most common cause of post kidney 
transplantation UTI at RCWMCH, which may reflect the institutional range of 
microbiota as well as the powerful immunosuppression used. Sixty two children with 
a mean age of 10 years were followed up after kidney transplantation for a mean 
period of 36.9 months. Of these children, 40% developed UTI with KP as the most 
common causative organism (Esezobor et al., 2012). 
Hospital mortality statistics reflected the importance of studying hospital-acquired 
infections. A 2008 study on ventilator-associated pneumonia (VAP) at RCWMCH 
involving 230 paediatric intensive care unit (PICU) children aged 3.9 (IQR 2.2-9.1) 
months where 25% were HIV-infected, showed that after Acinetobacter baumanii, KP 
was the second most common VAP-defining isolate from bronchoalveolar lavage 
specimens. KP was responsible for 28.8% (15/52) of cases. Of all the study children, 
40 (17.4%) died during PICU admission, and a further 15.2% (n=35) died later 
(Morrow and Argent, 2009). 
1.7 Risk factors for KP BSI and ESBL-producing KP BSI in children 
Researchers have not clearly defined factors predisposing hospitalised children to 
bloodstream KP infections for African children. However, risk factors that were 
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identified in other geographical settings may also influence the risk of acquiring KP 
BSI in African children. A recent American paediatric study identified 3rd-generation 
cephalosporin use in the previous 30 days as a significant risk factor for ESBL-
producing KP infection (Zaoutis et al., 2005). 
A 5-year review in Korea involving 157 blood isolates from children showed prior 
hospitalisation, PICU admission in the previous month, and prior exposure to 3rd 
generation antibiotics as risk factors for acquisition of ESBL-producing 
Enterobacteriaceae. The study population had similar clinical features. However, 
mortality was higher in children with ESBL-producing strains of E Coli and KP 
compared with those who had non-ESBL-producing isolates, 12 of 45 (26.7%) versus 
5 of 87 (5.7%) (P = 0.001) (Kim et al., 2002). 
A 2-year prospective study on febrile neutropaenic cancer patients in Kuala Lumpur, 
Malaysia showed KP as the causative agent in BSI in 29 children. This accounted for 
44% of all Enterobacteriaceae BSI in a paediatric oncology unit where leukaemia and 
lymphoma were the two most common underlying cancers in 18 and 4 children 
respectively. The mean age was 76.9 months. Hospitalisation for longer than 2 weeks 
and exposure to 3rd generation cephalosporins within 2 weeks prior to presentation 
were significantly associated with presumed ESBL-KP infection in a multivariate 
analysis: adjusted odds ratio (aOR) 14.9(95% CI 2.3-99.6) and aOR 11.1(95%CI 1.3-
95.2) respectively. Additionally, researchers associated delays in effective antibiotic 
treatment with increased mortality, OR 9.9 (95%CI 1.5-52.3) (Ariffin et al., 1999). 
In neonates, researchers described risk factors such as low birth weight, length of stay 
(LOS), duration of TPN, prolonged ventilation(>7days), and exposure to any 
antibiotics in the univariate analysis. Duration of TPN was the only independent 
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multivariate risk factor for acquisition of Gram-negative BSI including Klebsiella spp. 
BSI (Samanta et al., 2011). 
A clinical study in adults with KP BSI indicated that the presence of a CVP catheter and 
mechanical ventilation are significant adjusted risk factors for ESBL KP (Tuon et al., 
2011). In another study, univariate analysis identified dialysis, solid-organ 
transplantation, chronic liver disease, and cancer as risk factors for acquiring KP BSIs 
in a population-based study and were associated with a 20% mortality rate 
(Meatherall et al., 2009). In contrast, researchers in a further adult study found older 
age group (>60years), length of hospitalisation, and prior antibiotic exposure to be 
significant factors associated with ESBL-KP acquisition (Tumabarello et al., 2006). 
It is clear that there is limited information on paediatric KP BSI as well as on the risk 
factors for acquisition of ESBL-strain infection. Three paediatric studies have been 
found that specifically addressed KP BSI: two retrospective descriptive case series 
with limited risk factor analyses and one prospective descriptive study on febrile 
neutropaenic children with cancer. Together, these studies involved 186 children 
with KP BSI (see Table 1.5).  
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Table 1.5: Risk factors for ESBL-strain acquisition in paediatric studies 
involving Gram-negative (including Klebsiella pneumoniae (KP)) 
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ESBL-EC: ESBL-producing Escherichia Coli 
ESBL-KP BSI: ESBL-Klebsiella pneumoniae bloodstream infection 
GN BSI: Gram-negative bloodstream infection including Klebsiella 
CVP: central venous catheter 
AB: antibiotic 
N/A: not analysed
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1.8 Laboratory identification 
Effective management of a child with a KP BSI requires rapid recognition with timeous 
and correctly taken blood cultures followed by the laboratory’s rapid and accurate 
detection and identification of the organism. In Cape Town, South Africa, this is 
accomplished through the use of an automated system known as Vitek®2, to rapidly 
identify bloodstream infection coupled with disc diffusion susceptibility testing 
following international standards and guidelines. (Bamford C, personal 
communication) Detailed descriptions of the microbiological methods are given in 
section 2.4: Laboratory procedures. 
1.9 Treatment 
Healthcare providers should institute rational empiric antibiotic regimens early, 
before the laboratory results have been finalised, since delays or incorrect antibiotic 
choices are associated with increased mortality (Schwaber and Carmeli, 2007). 
During the study period, commonly chosen antibiotic combinations for a suspected 
nosocomial infection at RCWMCH were either a 3rd generation cephalosporin such as 
ceftriaxone or cefotaxime in combination with amikacin, an aminoglycoside, or 
piptazobactam in combination with amikacin. The present study should indicate 
whether these combinations remain appropriate for bloodstream KP infections at this 
institution. During the study period, healthcare providers commonly used ampicillin 
and gentamicin as empiric antibiotic therapy for all children with suspected 
community-acquired BSI, including children with severe or acute malnutrition. The 
high mortality reported in patients with bloodstream KP infections lends urgency to 
strengthening antibiotic stewardship and a surveillance system that would provide 
current and appropriate treatment guidelines.  
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1.10 Rationale for this research project 
The above literature review indicates that BSI caused by KP may constitute a serious 
health problem for affected children with a high mortality risk. There are, to date, no 
comprehensive studies specifically describing the burden of hospital acquired KP BSIs 
in South African children.  
At RCWMCH, researchers found Enterobacteriaceae to account for 64% (1 074/1 679) 
of all Gram-negative pathogenic isolates and 36.2% (1 074/2 969) of all pathogens in 
an audit of blood cultures taken over a 5 year period, 2008-2012. Of the 
Enterobacteriaceae, KP was the dominant species causing BSI (41.8%). On a positive 
note, the annual proportion of infections caused by KP isolates have shown a steady 
decline from 45.8% in 2008 to 31.7% in 2012 (χ2 for trend p=0.004) (Lochan et al., 
2013). 
Healthcare providers neither provided screening nor practised universal contact 
precautions at this institution. Poor infection control practice, especially suboptimal 
application of contact precautions including hand washing or by seasonal 
overcrowding such as is common in the RCWMCH short stay ward (SSW), may be 
largely responsible for the dissemination of resistance plasmids. Sick patients may be 
referred from the SSW for admission to the wards in the main hospital or those at 
other district or secondary hospitals in Cape Town. Overcrowding increases the 
susceptibility of the healthcare setting to heavy contamination. In the SSW, patient 
cots are often placed too close together with less than an arm’s length between them; 
several children may share the resuscitation couches in the emergency room at any 
one time. These practices occur in order to accommodate high numbers of children, 
but in so doing commonly lead to a breakdown in infection control practices. 
Overcrowding and increased patient to healthcare staff ratios throughout the hospital 
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often accompanied overcrowding in the SSW. High numbers of patients can even 
pressure surgical wards into accepting non-surgical patients in order to 
accommodate high numbers of sick children during seasonal caseload surge 
conditions. 
Managing patients with nosocomial infections is expensive and challenging with 
respect to treatment options and patient survival. The cost of an uncomplicated stay 
in a general ward bed at this children’s hospital during the study period was R2000 a 
day; stay in the PICU costs at least 4 times more (RCWMCH Hospital electronic patient 
Data system, CliniComTM Application Manager, 2012). Healthcare providers may 
expect children with healthcare associated sepsis to require considerably more 
resources than the admitting diagnosis predicted and suffer considerable morbidity. 
From what has been written on the epidemiology of paediatric KP BSI, the knowledge 
outcomes are severely limited. This paves the way for an in-depth analysis on the 
subject. Researchers have not evaluated the clinical profile of children with KP BSIs at 
this institution. The focus of this project is to explore the problem of laboratory 
confirmed KP bloodstream infections (LCBSI) in hospitalised children by linking 
patient demographics, clinical data, antibiotic resistance patterns, and clinical 
outcome in order to describe the emerging problem of multi-drug resistant KP BSI at 
RCWMCH. 
Additionally, a specific study objective was to uncover potential predisposing factors 
unique to hospitalised South African children in order to improve awareness and 
highlight the gravity of the outcome of hospitalised children that acquire nosocomial 
KP infections. By describing the antibiotic resistance profiles, the hope is to provide 
some clarity to rational antibiotic choices. Healthcare providers could also use the 
information thus generated to direct feasible preventive strategies once they know 
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potential risk factors. This information may also be useful in developing effective 
treatment strategies at this hospital and could inform other state hospital practices. 
In a parallel study, researchers recently showed the effect of methicillin resistant 
staphylococcus aureus (MRSA) at RCWMCH to account for 53% of 32 deaths attributed 
to Staphylococcus aureus BSI in a 5-year epidemiological review of staphylococcus 
BSIs. The authors of this study documented 365 cases of Staphylococcus aureus BSI 
over a 5-year period, 2008-2012. Multidrug resistant MRSA caused 26% (95/365) of 
the cases and was the only significant risk factor for mortality. Malnutrition, residents 
of intermediate care health facilities, and age of less than 12 months posed the 
greatest risk factors for acquisition of MRSA BSI (Naidoo et al., 2013). The clinical 
significance of the results of this study was substantial. Healthcare providers used the 
information to improve patient outcomes by improving empiric therapy and avoiding 
delays in therapy initiation for children with staphylococcal BSIs. Finding the 
appropriate antibiotic cover for healthcare- associated KP BSI would further enhance 
patient care at the institution. 
1.11 Aim and objectives 
1.11.1 Main aim 
The main aim was to describe the emerging problem of multi-drug resistant KP BSIs 
at RCWMCH. 
1.11.2 Specific objectives 
(1) The first specific objective was to describe the presentation of KP BSIs at 
RCWMCH over a 6-year period. 
(2) The second objective was to describe the spectrum of risk factors associated 
with ESBL- KP BSI. 
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(3) The third objective was to compare health-care related and community 
acquired KP BSI. 
(4) The fourth objective  was  to evaluate the antibiotic susceptibility patterns of 
Klebsiella pneumoniae isolates and the antibiotic selection and response to KP-
blood stream infections 
(5) The fifth objective was to evaluate cause of death and factors associated with 
inpatient mortality. 
(6) The final objective was to assess the outcome of KP BSI in HIV-infected and 
uninfected children. 
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CHAPTER TWO: METHODS 
2.1 Study design and setting 
This study was a hospital-based, retrospective case folder review conducted at Red 
Cross War Memorial Children’s Hospital (RCWMCH) from 1 January 2006 to 31 
December 2011. 
RCWMCH is a public sector hospital for children aged 0-13 years; it is also an academic 
teaching hospital. Doctors assessed an average of 3500 new children per month 
(range 3000 to 6000 per month) in the medical emergency unit and hospitalized up 
to 23 000 children per year. It is one of the two local tertiary referral units servicing 
1.5 million children under 14 years of age in the Western Cape. (STATS SA, 2011) It 
also serves as a national referral centre for children with selective sub-specialist 
problems. The hospital has a 20-bed multidisciplinary PICU, an 18-bed burn unit, a 
17-bed Oncology unit, 60 mixed surgical beds, 58 general paediatric beds, 29-bed 
ward for cardiology and tracheostomy patients, 29 sub-specialty medical beds, 10-
bed trauma unit, and 42 short stay medical beds. Admission numbers peak during 
seasonal diarrhoeal months, January to April, and overcrowding in the SSW becomes 
the norm with staff accommodating up to 90 children in this ward. Many children 
requiring admission into the main hospital beds frequently start their hospital stay in 
the SSWs. The main entry points into the hospital are via the medical emergency or 
trauma units. 
2.2  Study population 
Most of the children admitted to this hospital came from homes in low socioeconomic 
peri-urban settlements in the Western Cape Province. Some admissions were inter-
hospital transfers from neonatal units, secondary, and district level hospitals within 
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the province. The Medical Microbiology laboratory of the National Health Laboratory 
Service (NHLS) identified and forwarded an electronic list of all children hospitalised 
at RCWMCH with Klebsiella pneumoniae (KP) bloodstream infection (BSI) from 1st 
January 2006 to 31st December 2011.  
2.3  Data collection 
The first part of the review focused on hospital case notes of all the children who 
experienced KP BSI. Data included paper-based hospital case notes including patient 
demographics, age determined from the date of birth and current hospital admission, 
and HIV and nutrition status. These also included medical information including 
admission diagnosis, underlying medical conditions, previous medical history, clinical 
information regarding the BSI, antibiotic administration, potential risk factors for 
ESBL-producing BSI and mortality, length of hospital stay, and outcomes such as 
whether individual patients died during the current admission or discharged alive. 
Part of the extracted information included routine laboratory information from the 
NHLS database: full blood count (FBC) and differential, C-reactive protein (CRP), 
procalcitonin (PCT), urea and electrolytes, serum creatinine, prothrombin time (PT), 
activated partial thromboplastin time (APTT), fibrinogen level, blood gas, alanine and 
aspartate aminotransferase, and serum bilirubin. A standardised data sheet was used 
to compile the information (see Appendix A).  
A clinician, Heloise Buys (HB), and a nursing sister affiliated to the paediatric 
infectious diseases unit (PIDU), Spasina King, captured all data on standardised data 
sheets. HB subsequently entered into an Excel electronic database. The data sheets 
and electronic database are contained within a locked office belonging to HB. 
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2.4  Laboratory procedures 
All the microbiological tests in this study were performed in an accredited NHLS 
laboratory. The laboratory utilised the automated BacT/ALERT® blood culture 
system. For blood culture bottles flagging positive with mono-morphic Gram-negative 
bacilli seen on Gram stain, a locally validated method of direct inoculation into the 
automated Vitek®2 system (bioMérieux, Inc, France) was used  (Bamford et al., 2010). 
Based on the method described by Bruins, this involved separation of bacteria by 
centrifugation at 1525g for 10 minutes of a 4ml aspirate from the positive blood 
culture bottle in a serum separator tube. Following removal of the resulting 
supernatant, the film of bacteria sitting on top of the gel layer was re-suspended in 
3ml of 0.45% saline to a density of 0.6 – 0.8 McFarland standard. Vitek ID-GNB and 
AST-N064 cards were used for identification and susceptibility testing respectively 
(Bruins et al., 2004). 
The current Clinical and Laboratory Institute (CLSI) criteria helped to interpret 
antimicrobial susceptibility results (CLSI, 2012). If necessary, this also included 
alternative identification and susceptibility methods, including biochemical reactions, 
disc diffusion susceptibility testing, Etest minimum inhibitory concentration (MIC) 
testing, and further Vitek testing performed from bacterial colonies subcultured onto 
agar plates. 
ESBL production was inferred based on MICs/growth rates of various cephalosporins 
with/without inhibitors either via the Vitek 2, or by double disc synergy testing.  If 
ESBL production was detected, all cephalosporins, excluding cephamycins, were 
reported as resistant, irrespective of MIC or zone size. This study reported all known 
cephalosporins, excluding cephamycins, as resistant if detecting ESBL production, 
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irrespective of MIC or zone size. Specific reporting or documentation in laboratory 
information system of ESBL production has been quite inconsistent nationally. 
Therefore, for surveillance purposes, the NHLS laboratory relied on the pattern of 
antibiotic resistance and assumed that resistance to cefepime was equivalent to 
presence of ESBL for Enterobacteriaceae. The Vitek expert system infers presence of 
ESBL based on MICs or growth rates of various cephalosporins with or without 
inhibitors. 
2.5  Case Definitions 
 
 Healthcare-associated infection(HAI): 
 A community-onset Klebsiella pneumoniae blood stream infection confirmed on a 
blood culture specimen that was obtained within 48 hours of hospital admission in a 
patient with 1 or more healthcare-associated risk factors (HRFs). 
o Healthcare-associated risk factors (HRFs) 
- Presence of an invasive medical device e.g.,  vascular catheter 
- Surgery, hospitalisation, dialysis or residence in an intermediate 
healthcare facility in the preceding 12months of admission 
- History of KP infection or colonization (adapted for this study) 
 
 Nosocomial infection 
A blood stream infection was deemed nosocomial if Klebsiella pneumoniae was 
confirmed on a blood culture specimen that was obtained more than 48 hours after 
admission to hospital, or within 48 hours of discharge from hospital, with or without 
HRFs (Klevens et al., 2006).  
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 Community-acquired infection (CAI) 
A Klebsiella pneumoniae blood stream infection confirmed on a blood culture 
specimen that was obtained within 48 hours of admission to hospital, with no 
associated HRFs.  
 Healthcare-related infection 
All children who met the definition of either healthcare-associated or nosocomial BSI 
 Presumed ESBL-producing KP (ESBL KP) 
Based on the pattern of antibiotic resistance at the NHLS laboratory, for 
Enterobacteriaceae including Klebsiella pneumoniae isolates, resistance to cefepime 
was inferred equivalent to presence of ESBL.  In this document presumed-ESBL-
producing KP will be referred to as ESBL-KP. 
 Acute diarrhoea 
The production of 3 or more loose stools per day for less than 14 consecutive days 
(WHO, 2005).  
 Chronic diarrhoea 
The production of 3 or more loose stools per day for a minimum of 14 consecutive 
days (WHO, 2005).  
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 HIV infection 
A positive HIV DNA PCR result in any child < 18 months old, or 2 positive serological 
test results (HIV ELISA or HIV Rapitest) or a positive HIV DNA PCR result in a child > 
18 months old are considered HIV-infected (Centers for Disease Control and 
Prevention, 2008). 
 Unknown HIV status 
Any infant of child where there was no record of HIV testing at the NHLS laboratory 
database and whose mother’s HIV status was unknown. 
• HIV-exposed status 
Any infant of child where there was no record of HIV testing at the NHLS laboratory 
database and whose mother’s HIV status was known to be positive. 
 Definition of severe immunosuppression by CD4 lymphocyte percentage and count 
Any HIV-infected infant or child with a percentage CD4 or absolute CD4 count below 
the ranges set out in the using the 2006 WHO definitions (WHO, 2006) as summarised 
in Table 2.1. 
Table 2.1: Threshold CD4 cell count and percentage levels for severe HIV 
immunodeficiency in infants and children 
 
       
Percentage CD4 (%)   Age  months (m)   
Absolute CD4 count 
cells/mm3    
<25  < 11 m  <1500   
<20  12 - 35 m  <750   
<15  36 - 59 m  <350   
<15  >60 m  <200   
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 Nutritional status 
Moderate and severe underweight were classified  as weight-for-age z score 
(WAZ) between -2 and -3 standard deviations (SD) below the median using 
World Health Organisation (WHO) growth reference standards, and a WAZ < -3 
SD respectively. Weight-for-age z-scores were calculated from the 2000 Centers 
for Disease Control and Prevention (CDC) Growth Reference Standards in the 
United States  using the STATA command: egen zwaus= zanthro(wa, us), from 
“Standardizing anthropometric measures in children and adolescents with new 
functions for egen” (Vidmar et al., 2004).  
 Polymicrobial BSI 
A BSI in which Klebsiella pneumoniae and one or more bacterial pathogens other 
than Klebsiella pneumoniae were isolated from a single blood culture specimen.  
 
 Laboratory investigations 
Reference is made in this document to laboratory investigation results; with the 
exception of the HIV testing and the CD4 lymphocyte counts, these results were 
captured if the tests were taken on the same day as or within 48 hours of the KP blood 
culture. In the case of the CD4 lymphocyte counts the most recent result was captured; 
in South African state institutes CD4 lymphocyte monitoring is done at baseline and 
then at 6-12 monthly intervals (Meyers et al., 2005). In this study the latest recorded 
CD4 count did not necessarily correspond with the timing of the BSI but in all cases 
where documented fell within the preceding 3 month period. 
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 Haematological indices 
 Anaemia was defined as a blood haemoglobin level less than 11g/dl (WHO, 
2011). 
 Leukopaenia was defined as a white blood cell count below the reference 
range for age. 
 Thrombocytopaenia was defined as a platelet count < 150 × 109/L. 
 Bicytopaenia was defined when there was reduction in two of the three main 
blood cell lines. 
  Pancytopaenia was defined by the reduction of the three formed elements of 
blood below the normal reference ranges for age i.e., anaemia :haemoglobin 
,11g/dl; thrombocytopaenia: platelet count <150 x 109/L and leukopaenia: 
white blood cell count < age-related reference range 
 
 Coagulopathy was defined as an elevated out of age range prothrombin time 
(PT) of ≥ 2seconds; or an activated partial thromboplastin time (APTT) of 
≥60s or a depressed fibrinogen level of <2 µmol/L (Goldstein et al., 2005 and 
Angus et al., 2013) 
 
 Infective biomarkers 
 Procalcitonin (PCT) was considered elevated if the value was >0.5 µg/L 





 33  
Other organ dysfunctions 
 Liver dysfunction 
Where measured, serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and bilirubin were used as biomarkers of liver 
dysfunction. Specifically dysfunction was assumed when one or more of the liver 
enzymes markers were elevated to twice or more of their normal values or the 
bilirubin was >70µmol/L (excluding new-born infants) (Goldstein et al., 2005 
and Angus et al., 2013).  
 
 Renal dysfunction 
Where measured, the serum creatinine expressed in µmol/L was used as a 
biomarker of renal dysfunction. In the current study renal dysfunction was 
defined as a serum creatinine above the upper limit (>97.5th percentile) for 
paediatric age group. Renal function assessment is now commonly performed by 
assessing the estimated glomerular filtration rate (eGFR) which is further 
dependent on gender, height and creatinine clearance. From this a determination 
of whether kidney injury (previously called renal impairment/ dysfunction) is 
present can be made.  In our study patient heights were not routinely 
documented in the hospital case notes during the admission periods and hence 
eGFR could not be determined (expressed in ml/min/1.73m2), additionally, as 
nearly two thirds of children were malnourished in terms of weight-for-age z-
scores, a default assumption of normal height could not be used to estimate the 
GFR. There is evidence that serum creatinine measurements still provide useful 
assessment of renal function and may be more appropriate in young children 
(Pottel et al., 2008, and Boer et al., 2010). At RCWMCH’s clinical chemistry 
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laboratory serum creatinine is determined using an enzymatic assay method in 
line with international recommendations and the results referenced against age-
matched reference ranges Lewington and Kanagasundaram, 2011). 
 
 Septic shock 
Carcillo described septic shock as a state of tachycardia with feeble peripheral 
pulses, capillary refill time >2seconds, reduced level of consciousness, mottled or 
cool hands and feet, and reduced urine output (Carcillo, 2003). 
On the other hand according to the Surviving Sepsis Campaign the presence of 
sepsis together with haemodynamic inadequacy: the need for inotropic agents to 
maintain a normal blood pressure (BP) for age; or the presence of hypotension 
(systolic BP<2 SD below normal for age); or 2 or more of:  metabolic acidosis 
with a base deficit of > 5mEq/L; blood lactate >4; capillary refill time >5 s; 
oliguria, core-toe temperature gap of more than 3oC constitute septic shock 
(Goldstein et al., 2005 and Dellinger et al., 2012) However, in this retrospective 
study, the diagnostic criteria, clinical and treatment decisions made by the 
attending clinicians under the guidance of specialists stood, and their 
documented assessment of sepsis and shock were used to define a binary 
parameter of whether there was septic shock present or not. 
 
 Respiratory failure 
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 Excoriated skin 
Excoriative skin lesions , including burn wounds, that were significant enough to 
merit documentation in the medical or nursing notes were captured as a binary 
parameter: excoriated skin  or not.  Skin failure is a recognised dermatological 
entity describing a loss of skin integrity interfering with the barrier protection 
mechanism against mechanical damage and microbial penetration as well as 
other skin functions such as temperature regulation, fluid, electrolyte and 
protein retention. (Irvine, 1991)These functions are not directly amenable to 
laboratory testing but assessed visually and described by area, extent, site and 
depth of skin necrosis where possible.   
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2.6  Data analysis 
Using the patient identifiers obtained from the microbiology database, clinical and 
laboratory data were extracted retrospectively from the hospital folders, and together 
with antibiotic sensitivity results obtained from the GSH microbiology database, 
entered on a standardised data collection sheet (Appendix A). The data was entered 
anonymously in an Excel spread sheet by a single investigator (HB) and analysed 
using STATA Statistical software, release 11, (College Station, Texas, USA). 
Firstly, conventional descriptive methods, mean ± SD or median [interquartile range], 
were used to describe the dataset. The Shapiro-Wilks method helped with evaluating 
the distribution of continuous variables for normality. The non-parametric analytic 
methods, Kruskal-Wallis equality of populations’ rank test or Wilcoxon rank-sum test 
for independent samples, then helped to compare continuous variables. These 
variables included the median age of children who died versus that of those who 
survived and the Chi-squared or Fisher exact test used to compare categorical 
variables. The Wilcoxon rank-sum test helped to compare medians within two groups 
where data were continuous.  
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Risk factor analysis  
Univariate analysis helped to identify factors that were possibly associated with the 
risk of ESBL-KP infections. The subsequent multivariate analysis included variables 
with a p-value <0.1 using generalised linear modelling using Poisson regression with 
robust error variance to explore and quantify their relationships while correcting for 
confounders. These variables included gender, age, nutrition status, HIV infection, 
exposure to antibiotics, chronic underlying medical conditions, and ward 
management exposures such as intravenous (IV) fluid infusions, central vascular 
catheters, ventilation, and surgery. Given the high prevalence of ESBL-associated 
infections (83%), Risk Ratios with Confidence Intervals (CI) of 95% helped to quantify 
the measure of effect between groups after controlling for confounders.  
Univariate analysis helped to identify factors that were possibly associated with risk 
for mortality, and the subsequent multivariate analysis included any variables with p-
values <0.1 using generalised linear modelling. These variables included gender, age, 
nutrition status, HIV infection, exposure to antibiotics, chronic underlying medical 
conditions, and ward management exposures such as IV infusions, ventilation, and 
surgery. Given the high prevalence of mortality (30%), Risk Ratios with Confidence 
Intervals (CI) of 95% helped to quantify the measure of effect between groups after 
controlling for confounding factors. Additional sub-analyses proved useful when 
exploring differences in the group of children that died early, within 3 days and within 
14 days of the bacteraemic event, and later in the admission, >14 days after the BSI, 
as well as the group of children who presented with diarrhoeal disease. 
Both the univariate and multivariate analyses included using a significance level of p< 
0.05; 95% confidence intervals were quoted where relevant.  The basis for infection 
rates was infections per 1000 hospital admissions.  
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2.7 Ethical issues 
The study was approved by the Health Sciences Faculty Research Ethics Committee 
of the University of Cape Town (HREC REF: 367 /2009) and the Research Committee 
of RCWMCH. The study was done in accordance with the Declaration of Helsinki, 
(2008). Since the researchers collected data retrospectively, individual consent was 
not obtained from parents/legal guardians. The data sheets included the folder 
numbers of patients to enable the researchers to check information from the folders 
after data collection was completed. Each folder number was linked to a study 
number. Study numbers (but not names) were entered on an electronic database for 
anonymous analysis and reporting. The paper-based data sheets were kept in a locked 
office (HB) and the electronic database was encrypted using a password and available 
only to HB. 
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CHAPTER THREE: RESULTS 
The total number of KP BSI, the number of presumed ESBL KP BSI and the number of 
non-ESBL BSI per annum for the period 2004 until 2012 at Red Cross War Memorial 
Children’s Hospital (RCWMCH) is shown in Figure 3.1. The present study, which 
analyses KP BSI during the period 2006-2011, is nested within this graphical analysis.  
Figure 3.1: Klebsiella Pneumoniae bloodstream infections at RCWMCH 
January 2004- December 2012 
 
RCWMCH: Red Cross War Memorial Children’s Hospital 
KP BSI: Klebsiella pneumoniae bloodstream infection 
ESBL KP: extended-spectrum β-lactamase producing Klebsiella pneumoniae  
 
3.1 Incidence rates of ESBL KP and non-ESBL KP BSI 
The annual incidence of KPBI in 2006 was 3.23 cases per 1000 hospital admissions 
with a mean frequency of 2.54 ESBL and 0.54 non-ESBL cases per 1000 hospital 
admissions per year. The incidence of ESBL-KP infections increased from 2007 to 
peak in 2009 and then declined to 1.76 cases per 1000 in 2011. The incidence of non-
ESBL KPBI has declined from an incidence of 0.92 cases per 1000 to 0.43 over the 
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Figure 3.2: Incidence of ESBL- and non ESBL-producing Klebsiella 
pneumoniae bloodstream infections at RCWMCH 2004-2012 
 
ESBL-KP BSI: extended-spectrum β-lactamase producing Klebsiella pneumoniae bloodstream 
infection 
3.2  Characteristics of the study population 
Over the 6 year study period, January 2006 to December 2011, 410 hospitalised 
children had laboratory confirmed KP BSI; 339 (83%) of these were ESBL-related 
infections. The median age of the 410 children was 5.0 months, interquartile range 
(IQR) 2 to 16 months with 68.9% (282) being less than 12 months of age. There were 
212 males and 198 females. Of all children, 33 (8%) resided in intermediate 
healthcare facilities.  
Demographic information was complete for all 410 children and clinical data was 
complete for 407 children (see Table 3.1). Table 3.1 displays the results comparing 
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Table 3.1: Baseline characteristics of the children with Klebsiella 
pneumoniae bloodstream infection 
Variable All ESBL-KP Non-ESBL-KP 
Number of children (%) n=410 n=339 (83%) n=71 (17%) 
Male: female 212: 198 170: 169 42: 29 
Median[IQR] age in 
months 
5 (2-16) 5 (2-5) 10 (2-29) 
Median weight-for-age z-
score (IQR) 
-2 (-4 to -1) -2 (-4 to -1) -1 (-3 to -1) 
Moderate under-weight-
for-age n/N (%) 
78/410 (19.0) 66/339 (19.5) 12 /71 (16.9) 
Severe underweight-for-
age n/N (%) 








KP: Klebsiella pneumoniae 
IQR: interquartile range 
n/N: stratum specific proportions 
*HIV prevalence known in 288 children 
3.2.1 Nutritional status 
Regarding nutritional status, 241 (58.8%) children were moderately or severely 
underweight-for-age (UWFA) with 163 (39.8%) children severely UWFA. The median 
weight-for-age z-score (WAZ) was -2 (IQR -3.4 to -0.9). This study could not include 
height-for-weight and weight-for-height assessments since healthcare providers did 
not routinely document height in the hospital case notes during the admission 
periods. There were more children with ESBL-KP BSI [n=209/339 (61.7%)] who had 
moderate or severe underweight for age than those who had non-ESBL KP BSI, 
[n=32/71 (45.1%); p=0.01; RR 1.37 (95%CI 1.04-1.79)]. 
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3.2.2 HIV status 
Regarding HIV status, 206 (50.2%) children were HIV negative, 82 (20%) were HIV-
infected, and the HIV-status was unknown in 122 (29.8%) children (see Figure 3.3). 
There were equal numbers of male and female infected-children. Compared with 
uninfected children, more HIV-infected children, 61 (74.4%), were moderately or 
severely UWFA [RR1.22 (1.03-1.44)]. HIV infection was significantly associated with 
ESBL infection compared with non-ESBL KPBSI on univariate analysis (Fisher’s exact 
p =0.001, RR (RR 1.17, (1.08-1.26)). Only 3 (3.7%) HIV-infected children had non-
ESBL infections. Of the present study’s 82 HIV-infected children, 52/82(63.4%) 
presented with diarrhoeal disease, 35/82 (42.7%) presented with pneumonia, 14/82 
(17.1%) presented with both. 
Figure 3.3: The HIV status of the 410 study children with KPBSI 
 
 
The CD4-lymphocyte count performed within 3 months of the BSI, was known in 
71/82 (86.6%) of all HIV-infected children. Their median CD4-lymphocyte count was 
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of 71 (59.2%) children were severely immunosuppressed by CD4%-for-age, and 
55/71 (77.5%) severely suppressed by absolute CD4-lymphocyte count-for-age. Of 
the 71 children, 55 (77.5%) were severely immunosuppressed for age by both CD4% 
and absolute count using the 2006 WHO definitions.  
Of the 82 HIV-infected children, 41 (50%) were on antiretroviral therapy (ART) at the 
time of the KP BSI. The median time on ART before the KP BSI was 19 (IQR 8-66) days 
(see Figure 3.4). There was a progressive increase in the numbers of HIV-infected 
children on ART over the study period 2006-2011: in 2006 14 HIV-infected children 
developed KP BSI and 2/14 (14.3%) were on ART at the time of the BSI, while in 2011, 
4 HIV-infected children developed KP BSI and all 4 (100%) were on ART at the time 
of the BSI 
 Figure 3.4: Number and proportion of HIV-infected children with KP BSI on 





















































KP BSI-Klebsiella pneumoniae bloodstream infection ART-Antiretroviral therapy 
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3.3 Classification of KP BSI infections 
The infection was nosocomial or healthcare-associated in 389 (95%) children and 
community-acquired in 21 (5%). A graph shows the trend in the incidence of 
community acquired KP BSI over the 6 years. The nosocomial and HAIs increased 
from 2007, peaking in 2009 and declining again in 2011 (see Figures 3.5).  Of the 
children who acquired the infection within the community, 9 (2.2%) had been 
hospitalised within the previous 12 months. 
Figure 3.5: Incidence rates of Klebsiella Pneumoniae bloodstream infection 




The prevalence of non-ESBL and ESBL KP BSI by year 
Table 3.2 summarises the prevelance of KP-BSI infections over the study period. 
Throughout the study period, nosocomial BSI caused by ESBL-producing isolates 
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producing isolates remained low. Futhermore, there has been a 47% reduction in 
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3.3.1 Comparison of healthcare-related and community-acquired KP 
BSI in 410 hospitalised children 
When comparing children who acquired the BSI in the community with children who 
either were in hospital or were resident in intermediate healthcare facilities, there 
were 389 (94.9%) children with HRF compared to 21 (5.1%) children without 
(community-acquired KP BSI). Children admitted with community-acquired (CA) KP 
BSI were significantly younger at a median age of 1.5 (IQR 0.7-3.8) months compared 
with children who had healthcare-related KPBSI, their median age was 5.5 (IQR 1.9-
16.2) months, p-value=0.01. 
3.3.2 Comparison of healthcare-related and community-acquired KP 
BSI 
In the adjusted analysis, children with HRF were more likely to: have ESBL-KP BSI, p-
value 0.001; adjusted risk ratio (aRR) 1.19 (95% CI 1.07-1.32); be resident in the PICU 
at the time of the BSI, p-value 0.01; aRR 1.05 (95% CI 1.01-1.09) or have a chronic 
medical condition, p-value 0.005; aRR 1.08 (95% CI 1.02-1.14). Infancy, however, was 
associated with having a community-acquired KP BSI, p-value=0.001, aRR 0.92 (95% 
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At the time of the KP BSI, children with HRF had a significantly lower mean 
haemoglobin value at 9.65 ±2.18 g/dl than 10.6 ±1.89 g/dl seen in children with 
community-acquired KP BSI, p-value=0.02. Whilst the median White blood cell (WBC) 
count and percentage band counts did not differ significantly, children with HRF had 
a lower median platelet count of 103 (IQR 32-288) x109/l compared with 350 (IQR 
193-659) x 109/l seen in those children whose infection was community-acquired, p-
value= 0.0001 (see Table 3.4).  
Table 3.4: Comparison of haematological and pro-inflammatory indices in 
children with healthcare-related KP BSI and community-acquired KP BSI at 
the time of the BSI 
 
Variable Children with HRF KP BSI# Children with CAI KP BSI$ p-value 
n/N (%) 389/410 (94.9) 21/410 (5.1) - 
Mean haemoglobin 
(±SD) g/dl 
9.65 (±2.18) 10.6 (±1.89) 0.02 
Median WBC (IQR) 
x109 /l count 
11.7 (6.24-19.8) 15.9 (5.07-26.3) 0.32 
Median platelet (IQR) 
x109/l count 
103 (32-288) 350 (193-659) 0.0001 
Median CRP(IQR) 
mg/l 
108 (38-194) 101.5 (50-240.5) 0.82 
Median PCT (IQR) 
ng/ml 
15.3 (1.9-41.7) - - - 
Percentage Median 
band (IQR) count 
14 (5-28) 15.5 (8.5-23.5) 0.89 
KP BSI: Klebsiella pneumoniae bloodstream infection 
#HRF: healthcare-related KP BSI; $CAI: community acquired KP BSI 
n/N: stratum specific proportions 
SD: standard deviation 
WBC: white blood cell 
IQR: interquartile range 
CRP: C-reactive protein 
PCT: procalcitonin 
 
 50  
3.3.3 Comparison of the complications and outcome of Healthcare 
and CA BSI 
There was no significant difference in the mortality risk in children with HRF 
compared to those who had community-acquired BSI; the median time to death from 
the time of the positive KP blood culture (IQR) days for those with HRF was 4 (1-13) 
days compared to 2.5 (0.5-6) days in those with CA BSI, p=0.37 . Children with HRF 
were more likely to experience respiratory failure but not experience renal injury (see 
















































































































































































































































































































3.4  Chronic underlying medical condition 
Of the study children, 64% (262) had a chronic underlying medical condition (see 
Table 3.6).  
Table 3.6: The chronic underlying medical condition in 410 hospitalised 
children with KP bloodstream infection 
Chronic medical condition Number Percentage 
Nil 148 36.1 
HIV disease 82 20.0 
Cardiovascular  54 13.2 
Gastrointestinal 50 12.2 
Malignancy 26 6.3 
Renal 19 4.6 
Neurological 14 3.4 
Tuberculosis 8 2.0 
Aplastic anaemia 3 0.7 




Congenital CMV disease 1 0.2 
Congenital cardiac lesions made up 91% (49 of 54) of all cardiovascular conditions. 
Gastrointestinal conditions included a heterogeneous spectrum with the most 
common being congenital intestinal atresias, biliary atresia, and gastroschisis. 
Chronic renal failure and hydronephrosis were the main renal conditions; 19 of the 
26 children with malignancy had either leukaemia or lymphoma. The remaining seven 
patients with malignancy had solid tumours. Ten of the 14 children with neurological 
disorders had spastic cerebral palsy and two had muscle disorders. Tuberculosis was 
deemed an underlying medical condition if the child was on anti-tuberculosis 
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treatment on admission to RCWMCH. There was one child with disseminated 
congenital cytomegalovirus infection (see Table 3.6). 
3.5 Prior hospitalisation exposure of 410 hospitalised children with 
Klebsiella pneumonia bloodstream infection 
Of the children, 230 (56.8%) had been hospitalised within the preceding 12 month 
period. By univariate analysis, they were as likely to have an ESBL-KP BSI compared 
to children who had not been hospitalised; however this difference was not 
statistically significant (see Table 3.7).  
Table 3.7: Prior (up to 12 months) hospitalisation exposure of 410 











Number of children 339/410 (83) 71 /410(17) - - 
Hospitalisation 
within previous 28 
days 




within previous 12 
months 
193/334 (57.8) 37/71(52.1) 0.38 
1.04 
(0.95-1.14) 
ESBL-KP: extended-spectrum β-lactamase producing Klebsiella pneumoniae 
n/N: stratum specific proportions 
 
3.6  The clinical presentation on admission to hospital of study 
children who developed KP bloodstream infection during 
hospitalisation at RCWMCH 
Over the six years, diarrhoeal disease and pneumonia were the two most common 
admission diagnoses in 137 (33.4%) and 91 (22.2%) of the study children 
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respectively (see Table 3.8). The other admission diagnoses formed a large 
heterogeneous group of conditions with no clear pattern. One hundred and eighty two 
(44.4%) children had more than one admission diagnosis.  
Table 3.8: The admission diagnoses of study children with KP bloodstream 
infection (n = 410) 
Top five principal admission  
conditions categories: 
n (%) 
Diarrhoeal disease 137 (33.4) 
Pneumonia 91 (22.2) 
Cardiac 46 (11.2) 
Neoplasm 29 (7.0) 
Burn wounds 27 (6.6) 
KP: Klebsiella pneumoniae 
The median hospitalisation time from admission to non-ESBL BSI (3days) was 
significantly shorter than that for the acquisition of ESBL-BSI (9days), p<0.0001, RR 
1.45 (1.21-1.74). Table 3.9 includes a summary of these findings. 
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410 (100) 339(83%) 71 (17%) - - 
Median time(IQR) 
to bloodstream 
infection in days 
7 (3-19) 9 (4-23) 3 (0-7) <0.0001 1.45 
(1.21-1.74) 
 
3.7 The clinical spectrum of KP-bloodstream infection over a 6 
year period 
At the time of the KP-BSI event, 206 (50.2%) children did not have a definable clinical 
focus of infection. Of the children, 70% (284) experienced fever of ≥38OC within the 
48 hours of the positive blood culture. The most common clinical problem was 
pneumonia in 30% of children. The range of other clinical presentations included: 
wound and soft tissue infections, peritonitis, necrotising enterocolitis (NEC), and 
urinary tract infections (UTIs). Healthcare practitioners saw in-dwelling vascular 
catheter-related infections and septic peripheral vascular catheter infections in 
21(5.1%) and 12 (2.9%) of the children respectively (see Table 3.10). 
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Table 3.10: The clinical site of infection in children with Klebsiella 
pneumoniae bloodstream infection  
No. with primary bloodstream infection without a 
definable focus 
206 (50.5%) 
Common sites of infection  
 Pneumonia 121 (29.7) 
 Vascular-catheter related  21 (5.1) 
 Peritonitis 20 (4.9) 
 UTI* 20 (4.9) 
 Septic wound and soft tissue 24 (5.9) 
 NEC# 20 (4.9) 
 Septic drip site(+ve$ culture of KP) 12 (2.9) 
 Cholangitis 4 (1) 
 Dysentery 3 (0.7) 
 Typhilitis 3 (0.7) 
 Bacterial endocarditis 1 (0.2) 
 Necrotic tumour 1 (0.2) 
 Bowel obstruction  1 (0.2) 
UTI*: urinary tract infection  
NEC#: necrotising enterocolitis  
+ve$ -positive 
3.8 Clinical comparisons of ESBL and non-ESBL infections at the time 
of BSI 
Comparisons made between children with and without ESBL-related KP BSIs at the 
time of the BSI showed that ESBL-KP BSI was more likely to manifest with pneumonia 
compared with non-ESBL-KP BSI, (p=0.04; 1.12 (1.02-1.21)). Children without an 
identifiable clinical focus were less likely to have ESBL-KP BSI (RR 0.88 [95%CI 0.80-
0.96]; p=0.004). Although 284 (70.1%) children experienced fever, axillary 
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temperature >38OC, this was not more likely to be associated with infection caused by 
ESBL-producing isolates (see Table 3.11). Other clinical events at the time of the blood 
culture were not significantly linked to ESBL-KP BSI.  
Table 3.11: The clinical diagnosis at the time of Klebsiella pneumoniae (KP) 
bloodstream infection 
Clinical diagnosis 
at the time of 
culture 
ESBL-KP BSI 
n /N (%) 
Non-ESBL KP BSI 
n /N (%) 
p value 




infection with no 
identified source 
159 /337 (47.2) 47/71 (66.2) 0.004** 
0.88 
(0.80-0.96) 
     
Temperature 





238/334 (71.3) 46 /71 (64.8) 0.28 
1.10 
(0.91-1.32) 





19/336 (5.6) 2/71 (2.8) 0.33 
1.10 
(0.95-1.28) 
Peritonitis 16/336 (4.8) 4 /71 (5.6) 0.76 
0.97 
(0.77- 1.21) 





18/338 (5.3) 2/71 (2.8) 0.37 
1.09 
 (0.94-1.28) 
     
Septic drip site 
(+ve culture of 
KP) 
11/337 (3.2) 1 /71(1.4) 0.40 
1.11 
(0.93-1.33) 
     
Soft tissue 
infection 





13 /336 (3.8) 1/71 (1.4) 0.30 
1.13 
(0.97-1.32) 
n/N stratum specific proportions 
** denotes significance at p<0.05 level 
ESBL-KP: extended-spectrum β-lactamase producing Klebsiella pneumonia 
BSI: bloodstream infection 
UTI: urinary tract infection 
 +ve: positive culture for KP from the septic drip site 
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3.9 Risk factors for ESBL infection 
On univariate analysis, age < 12 months,  moderate or severe underweight-for-age, 
HIV infection, resident in the PICU at the time of the KP BSI,  cephalosporin exposure 
during the 12 month period prior to the development of KP BSI, mechanical 
ventilation prior to BSI, intravenous infusion for more than 3 days prior to BSI, 
indwelling urinary catheter prior to BSI, major surgery prior to BSI and a previous KP 
infection in the 12 month period before the KP-BSI were significant risk factors for 
ESBL infection. 
 On multivariate generalised linear modelling analysis, cephalosporin exposure 
during the 12 month period prior to the development of KP BSI, HIV infection, and 
intravenous infusion for more than 3 days prior to BSI remained significant risk 
factors for ESBL infection (see Table 3.12). 
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Table 3.12: Spectrum of factors associated with presumed ESBL-Klebsiella 
pneumoniae bloodstream infection (BSI) 
         
 Risk factors for ESBL-   Univariate analysis  Adjusted analysis  
  KP infection  p-value;   RR$$ (95% CI)  p-value;  aRR (95% CI)  
 Age (infant vs. >1y)  0.014; 1.15 (1.03-1.28)  0.09;     1.10(0.99-1.24)   
 Gender   0.17; 0.94 (0.86-1.03)  - -  
 
Moderate or severe 
underweight for age 
 0.03;   1.11 (1.01-1.23)     0.23;   1.06 (0.96-1.16) 
 
 HIV-infection  <0.0001;  1.22 (1.13-1.30)  0.01;     1.12 (1.02-1.22)**  
 Patient in the PICU*  0.02;   1.11 (1.02-1.21)  0.36;     0.95 (0.84-1.06)  
 Inter-hospital transfer
$  0.15;    1.05 (0.99-1.12)  - -  
 
Cephalosporin 
exposure in the last 12 
months pre-BSI 




prior to BSI 




infusion>3days prior to 
BSI 




catheter prior to BSI 




procedure prior to 
BSI# 
 0.03;   1.11 (1.01-1.21)  0.85;     0.99 ( 0.88-1.11) 
 
 Excoriated skin  0.30;      1.05 (0.96-1.15)  - -  
 
Previous KP infection 
within last 12m 
 0.01;  1.14 (1.03-1.26)  0.94;       1.01 (0.89-1.14) 
 
                
         
 
$$ RR risk ratio; *PICU: paediatric intensive care unit;  # A major surgical procedure included a laparotomy 
(emergency or elective), a thoracotomy, a skin graft or a craniotomy, BSI, and bloodstream infection;  $ Inter-
hospital transfer: transferred from another hospital prior to the development of bloodstream infection;                                                                                                                                                                                                                                                                                                                                   
Multivariate model adjusted for HIV infection, age<12 months, underweight-for-age, mechanical ventilation, 
patient in the PICU at the time of the BSI, IV fluid infusion longer than 3 days prior to BSI, indwelling urinary 
catheter, major surgery prior to the BSI, Previous KP infection within last 12months, and cephalosporin 
exposure during last 12 months prior to BSI. aRR adjusted risk ratio. ** Factors with p-value <0.05 in the 
adjusted risk analysis; 
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3.10 Prior antibiotic exposure of hospitalised children with 
Klebsiella pneumoniae bloodstream infection 
In view of the high prevalence of children with chronic health conditions, it was 
important to conduct an analysis exploring the influence of exposure to antibiotics on 
the type of KP infection. The analysis revealed that 40% (155) of 387 children had 
taken at least one of the following antibiotics in the 12 months preceding current 
hospitalisation: 2nd and/or 3rd and/or 4th generation cephalosporins, 
fluoroquinolones, macrolides, cotrimoxazole, aminoglycosides, piptazobactam, and 
carbapenems. Exposure to any of the stated antibiotics was significantly associated 
with having an ESBL-producing KP BSI [p-value <0.0001; RR 1.97 (95% CI 1.52-2.57)] 
compared to a non-ESBL associated infection on the univariate analysis. 
On univariate analysis, significantly more children who received 2nd and/or 3rd 
and/or 4th generation cephalosporins, aminoglycosides, cotrimoxazole, 
carbapenams, and/or piptazobactam during the prior 12 months developed ESBL-KP 
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Table 3.13: Prior (up to 12 months) antibiotic exposure of hospitalised 




n /N* (%) 
Non-ESBL-KP 











     
Exposure to a 
selection of 
antibiotics** 
287/319(90) 31/68 (46.4) <0.0001 1.97 (1.52-2.57) 
     




190/205(92.8) 15 /69 (17.8) <0.0001 1.31 (1.19-1.46) 
     
Aminoglycosides  206/319 (64.6) 21/69 (30.4) <0.0001 1.30 (1.16-1.44) 
     
Cotrimoxazole 91/319 (28.5) 5/69 (7.3) 0.001 1.21 (1.12-1.31) 
     
Carbapenems 65/319 (20.4) 4 /69 (5.8) 0.004 1.18 (1.10-1.28) 
     
Piptazobactam 95/319 (29.8) 12/69 (17.4) 0.04 1.11 (1.02-1.22) 
     
Fluoroquinolones 48/319 (15.1) 7/69 (10.1) 0.29 1.07(0.95-1.20) 
# ESBL-KP: extended-spectrum β-lactamases producing Klebsiella pneumoniae 
* n/N: stratum specific proportions 
** Exposure to the following antibiotics within the last 12 months: 2nd and/or 3rd and/or 4th 
generation cephalosporins, macrolides, fluoroquinolones, cotrimoxazole, aminoglycosides, 
piptazobactam, and carbapenems 
 
3.11 Children presenting with diarrhoeal disease  
Diarrhoeal disease is a seasonal condition. Traditionally, the season is associated with 
the highest number of children presenting to the institution with subsequent 
overcrowding of all the wards. Therefore, it was helpful to include an exploratory sub-
group analysis for children presenting with diarrhoeal disease. 
 62  
In the study, 137 children presented with diarrhoeal disease, which was acute in 114 
and chronic in 23 children as one of their main admission complaints. In this group, 
58 of 137 (77%) children were infants. The case-fatality rate of children with KP-BSI 
who presented with diarrhoeal diease: 44/137 (32%) died, 41 who manifested with 
acute diarrhoeal disease and 3 who had chronic diarrhoeal disease. Furthermore, 
23/44 (52%) died within 3 days of the onset of BSI.  
By univariate analysis, children presenting with diarrhoeal disease were more likely 
to be moderately or severely UWFA. Their characteristics are summarised in Table 
3.14. They also had a shorter median time to the BSI after admission to hospital than 
those without diarrhoea; 5 versus 11 days, p<0.0001. Of 82 HIV-infected children, 
52/82(63.4%) presented with diarrhoeal disease compared with 30/82 (36.6%) who 
did not present with diarrhoeal disease, p=<0.0001.  
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Table 3.14: Comparison of characteristics and outcome of children with KP 









n   ( %) 
p value RR(95% CI) 
N (all=410) 137 (33.4%) 273 (66.6%) - - 
     
Gender(M:F) 66:71 146:127 0.31 0.87  (0.66-1.14) 
     
Median age 5.2 (2.2-11.1) 5.1(1.2-29.4) p = 0.48 - 
Moderate or 
severe UWFA 
96 (70.1) 145 (53.1) 0.001 1.32  (1.13-1.54) 
     
HIV-infection 52 (38%) 30 (11%) <0.0001 1.89  (1.47-2.44) 
     
ESBL KPBSI 119 (86.9) 220 (80.6) 0.11 1.38  (0.91-2.12) 
     
Median time to 
bacteraemia 
(IQR) days 
5 (3-9) 11 (4-25) 
 
p <0.0001 - 
     
Median time to 
death days 
(IQR) 
12 (5-25) 13 (6-32) 
 
p = 0.11 - 
     
Mortality 44 (32.1) 79 (28.9) 0.51 1.10 (0.82-1.51) 
KPBSI: Klebsiella pneumoniae bloodstream infection 
ESBL: extended-spectrum β-lactamase producing 
UWFA: underweight-for-age 
IQR: interquartile range 
 
3.12 Laboratory changes at the time of the bloodstream infection 
This section summarises haematological and pro-inflammatory results measured at 
the time of the KP BSI. 
3.12.1 Haematological changes 
Of the children, 71% (290/407) had normocytic normochromic anaemia at the time 
of the bacteraemic event. The mean haemoglobin was 9.7 g/dl SD ±2.18 and the 
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median mean corpuscular volume (MCV) was 84 (IQR 78-89) femtolitres. Children 
with ESBL-KP infection had a lower mean haemoglobin compared with those with 
non-ESBL infection, p=0.006. The differential WBC counts did not differ significantly 
between the two groups of children. The median platelet count, however, was 
significantly lower in the ESBL-infection group, p=0.003 (see Table 3.15). Anaemia 
was not more prevalent in children who were moderately or severely UWFA 
compared with those with normal weight-for-age z scores, 169/241 (71.6%) vs. 
121/169 (71.6%); p=0.75; RR 0.98 (95% CI 0.81-1.16). 
Elevated WBC were seen in 110 (33.7%) of 406 children with 223 (63.7%) of 350 
children showing a band count of ≥10%. Of the children, 62 (15.3%) were 
pancytopaenic at the time of the KP BSI. The healthcare providers also saw 
thrombocytopaenia in the absence of pancytopaenia in 161 (39.3%) children.  
 Coagulation disturbances were evident in 73 (57.5%) of 127 children tested. More 
children, 66/108 (61.1%), with ESBL-KP infection had evidence of a coagulopathy 









































































































































































































































































































































































































































































































































































































































































































































































































 66  
There were reductions of one or more haematological cell lines in many children (see 
Table 3.16). Normocytic anaemia was the most common finding. Thrombocytopaenia 
was the second most common finding and was significantly more common in children 
with ESBL-KP infection, p=0.046; RR 1.0 (1-1.20) than in those with a non-ESBL 
infection. Leukopaenia was uninfluenced by whether the KP-infection was ESBL-
related or not.  
Anaemia with thrombocytopaenia was the most common bicytopaenia and was more 
common in children with ESBL-KP BSI, p=0.002; RR 1.78 (1.17-2.70). Leukopaenia 
with thrombocytopaenia was also more common in children with ESBL-KP infection, 
p=0.05; RR1.12 (1.02-1.22). Pancytopaenia was more common in children with ESBL-
KP BSI, p=0.04; RR 1.13 (1.04-1.23) (see Table 3.16). 
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Table 3.16: Prevalence of haematological cell line reductions in 
hospitalised children with KP bloodstream infection 
Cell line ESBL n (%)            Non-ESBL n (%) p value;  
RR (95% CI) 
Anaemia (Hb<11) 246/339 
(72.6%) 
44 /71(62.0%) 0.07;  
1.09 (0.98-1.22) 




30 /68(44.1) 0.046;  
1.09(1-1.20) 


























186/294 (63.3) 37/56 (66.1%) 0.69;  
0.96 (0.78-1.18) 
Leucocytosis  110/337 (32.6) 27/69 (39.1) 0.3; 
0.83 (0.60-1.16) 
Hb: haemoglobin 
3.12.2 Infective markers: C - reactive protein and procalcitonin 
values at the start of the KP BSI  
In 287 children in whom the serum procalcitonin (PCT) or C-reactive protein (CRP) 
were determined, 263 (91.6%) had a raised PCT or CRP. This was uninfluenced by the 
ESBL status of the KP isolate (p=0.47) (see Table 3.17). 
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Table 3.17: C-reactive protein and procalcitonin concentrations at the time 
of KPBSI in children with Klebsiella pneumoniae Bloodstream infection 












































79/106 (74.5)  69/96 (71.9)  10/10 (100)  0.05 
n= number of cases 
n/N: stratum specific proportions 
ESBL: extended-spectrum β-lactamase producing 
CRP: C-reactive protein 
PCT: procalcitonin 
IQR: interquartile range 
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CHAPTER FOUR: ANTIBIOTIC SUSCEPTIBILITY PATTERNS OF 
KLEBSIELLA PNEUMONIAE ISOLATES AND ANTIBIOTIC THERAPY 
4.1 Antibiotic sensitivity patterns of the isolates overall 
All isolates, both ESBL- (339/410) and non-ESBL-producing (71/410), were resistant 
to ampicillin. Of these, 21% (86/410) were sensitive to gentamicin; in contrast, 76.1% 
(312) were sensitive to amikacin. Out of 349 tested, 211 (60.5%) were sensitive to 
piptazobactam; 117/402 (29.1%) isolates were sensitive to coamoxy-clavulinic acid. 
All isolates were sensitive to the carbapenems imipenem and meropenem, and 
402/404 (99.5%) isolates were reported sensitive to ertapenem.  
4.2 Antibiotic therapy 
Data on the antibiotic therapy that was instituted in response to the BSI were 
available in 398 children. Antibiotic therapy was considered appropriate if the NHLS 
laboratory reported the organism sensitive to the specific antibiotic. The empiric 
antibiotic prescribed in response to the BSI was appropriate in 307/398 (77.1%) 
children: 241/398 (73.5%) children with ESBL KP BSI and 66/70 (94.3%) children 
with non-ESBL KP BSI. Once laboratory results became available, healthcare 
providers adjusted the antibiotic cover; this delay did not reflect an increase in crude 
mortality p=0.29, RR 0.83 (95% CI: 0.59-1.16), there were 87/307(28.3%) children 
on appropriate empiric antibiotics who died versus 31/91 (34.1%) children on 
inappropriate empiric antibiotics. Table 4.1 summarises the susceptibility of KP 
isolates to antibiotics or antibiotic combinations that are frequently used in clinical 
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An initial empiric combination of ampicillin plus amikacin would have been effective 
in 90.5% (19/21) of community-acquired KPBSI whereas the combination of 
ampicillin plus gentamicin would have been appropriate in 71.3% (15/21). From the 
susceptibility patterns, ertapenem would have provided adequate cover to 356/358 
(99.4%) of nosocomially acquired KPBSI. 
4.2.1 Sub-analysis on antibiotic susceptibility patterns over two 
periods 2006-2008 and 2009-2011 
Antibiotic susecptibility patterns for KP isolates from 2006 to 2008 and 2009 to 2011 
are summarised in Tables 4.2 and 4.3 respectively. 
 In the first period 2006-2008 ertapenem would have provided 100% (187/187 
isolates susceptible), cover for all categories of KP BSI as empiric cover; however 
in the second period 2009-2011, cover was incomplete for suspected serious 
nosocomial KP BSI at 98.9% (187/189 isolates susceptible) but complete for 
community acquired infection (CAI) [(10/10 isolates susceptible)] and complete 
for healthcare-associated KPBSI (9/9 isolates susceptible). 
 Given the number of isolates, in the period 2006-2008 ampicillin plus gentamicin 
combination would have covered 6/11 (54.6%) isolates compared to a higher 
proportion 9/10 (90%) isolates for CAI in the period 2009-2011. 
 Regarding the combination of ampicillin plus amikacin as empiric broad-spectrum 
treatment of suspected community acquired infections, in the periods 2006-2008 
and 2009-2011, 10/11 (90.9%) of isolates and  9/10 (90%) isolates respectively 
were susceptible to this combination  
 The cover provided by the combination of ceftriaxone plus amikacin for 
nosocomial KP BSI declined markedly over the two periods 2006-2008 and 2009-
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2011 from 87.9% (152/173 isolates susceptible) cover to 64% (121/189 isolates 
susceptible) isolate cover. 
 Over the periods, 2006-2008 and 2009-2011, the cover provided by the 
combination of piptazobactam plus amikacin for nosocomial BSI diminished from 
91.8 %( 157/171 isolates susceptible) to 81.6% (142/174 isolates susceptible).  
 There was a shift in cefotaxime sensitivity from 45.5% (5/11) in the first period 
2006-2008 to 66.7% (9/10) in the second period 2009-2011. 
 Cover by co-amoxyclav for CAI over the two periods was higher at 81.9% (9/11 
isolates susceptible) and 90% (9/10 isolates susceptible) for CAI compared to 
28% (47/168 isolates susceptible) and 23.1% (43/182 isolates susceptible) for 
nosocomial isolate cover 
 Overall, the sensitivity patterns of KP isolates from children who had HCA BSI was 
very similar to those with nosocomial BSI (with respect to ampicillin plus 
amikacin; piptazobactam plus amikacin; ceftriaxone plus amikacin; and 
ertapenem), or was positioned between nosocomial and community BSI, (with 
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4.2.2 Profile of the non-ESBL isolates antibiotic sensitivity 
prevalence 
Of the 410 KP isolates, 71 (17.3%) were non-ESBL producers. They were all sensitive 
to cefotaxime, ceftriaxone (3rd generation cephalosporins) and cefepime (4th 
generation cephalosporin), amikacin, ciprofloxacin, and the carbapenems ertapenem, 
imipenem, and meropenem. The isolates were also sensitive to gentamicin, 
piptazobactam, and coamoxyclav in 94.4%, 91.6%, and 93.0% of cases respectively. 
Of the isolates, 53 of 71 (74.7%) were sensitive to cotrimoxazole. The combination of 
ceftriaxone plus amikacin would have provided adequate cover for all the children 
with non-ESBL KPBSI but would not have provided appropriate antibiotic cover for 
98 (28.9%) children with ESBL BSI. 
4.2.3 Profile of the ESBL isolates resistance patterns 
All isolates were resistant to ampicillin and cefotaxime, ceftriaxone and cefepime.  
Resistance to cotrimoxazole was reported in 313/339 (92.3%) isolates. Out of 339 
tested, 51 (15.0%) were sensitive to coamoxyclav; 241/339 (71.1%) of the isolates 
were sensitive to amikacin, and 146/282 tested (51.8%) were sensitive to 
piptazobactam. At the same time, 197/339 (58.1%) children had ciprofloxacin-
sensitive isolates. Additionally, the combination empiric therapy of piptazobactam 
plus amikacin would not have provided appropriate antibiotic cover to 50 (15.6%) 
children who had ESBL-KP BSI. The same empiric combination therapy would not 
have provided adequate cover for 9/33 (27.3%) children living in intermediate-care 
facilities. Bearing in mind that 96.3% (n=79) of the HIV-infected children had an ESBL 
infection, 26 (31.7%) would not have received appropriate cover if healthcare 
providers chose an antibiotic regimen consisting of ceftriaxone plus amikacin. All 
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isolates were sensitive to the carbapenems: imipenem and meropenem. Two were 
resistant to ertapenem (see Figure 4.3).  
4.2.4 ESBL and non-ESBL isolates from HIV-infected children 
Of the 82 HIV-infected children, 62 (75.6%) were on cotrimoxazole prophylaxis prior 
to the KP BSI. Of these infected children, 79 (96.3%) had ESBL-producing KP isolates 
compared to 3 (3.7%) who had non-ESBL KPBSI (Fisher’s exact p =0.001). The ESBL-
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4.3 Polymicrobial blood results 
Of the study children, 69/410 (16.8%) had more than one bacterial pathogen isolated 
in the same blood culture as the one identifying the KP. These organisms included (see 
Table 4.4): 
Table 4.4: Clinical features associated with polymicrobial blood culture 
results in 69 children 
Other organism in the 
blood culture  
n (%) Clinical features at the time of the blood 
culture 
Escherichia coli 20 29.0 8 Pneumonia,6 no focus,3 UTI, 2 NEC,1septic 
wound 
Enterococcus faecalis 11 15.9 5 Pneumonia, 4 no focus, 1 endocarditis, 1 CV- 
line-related 
ESBL KP(other) 8 11.6 5 Pneumonia, 1 no focus, 1UTI, 1 CV-line related 
Acinetobacter baumannii 7 10.1 5 No focus, 1 pneumonia, 1 septic wound 
Serratia species 6 8.7 4 No focus, 1 pneumonia, 1 bowel obstruction 
Enterobacter cloacae 4 5.8 2 No focus, 1 pneumonia, 1 NEC 
Staphylococcus aureus(SA) 3 4.4 2 No focus, 1 pneumonia 
Enterococcus faecium 2 2.9 2 Pneumonia 
Methicillin resistant SA 1 1.5 Pneumonia 
Streptococcus pneumoniae 1 1.5 Pneumonia 
KP oxytoca 1 1.5 Peritonitis 
Pseudomonas aeruginosa 1 1.5 No focus 
Citrobacter freundi 1 1.5 Peritonitis 
Candida species 1 1.5 Peritonitis 
Streptococcus mitis 1 1.5 No focus 
Staphylococcus 
epidermidis 
1 1.5 Pneumonia 
Total 69 100%  
UTI: urinary tract infection 
NEC: necrotising enterocolitis 
CV-line: central venous line 
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There were 30 female (43.5%) and 39 (56.5%) males. Their median age was 4.5 (IQR 
1.1-10.8) months, 52 (75.4%) were less than 12 months. Of the children, 12 (17.4%) 
were HIV-infected and 23 (33.3%) were untested (see Table 4.5).  
There was a concomitant underlying condition in 44 (63.8%) of the children. Four 
(5.8%) children had community acquired KPBSI; the other 65 (94.2%) had 
nosocomial infection or HAI; of these infections 53 (81.5%) were caused by ESBL-
producing isolates. The children did not appear to have any distinguishing clinical 
features; 52 had a temperature> 38°C at the time of the bacteraemic event. 
Children with polymicrobial BSI (54/69; 78.3%)were not more likely to have an 
ESBL-KP infection compared with children with single organism KP BSI (285/341; 
83.6%);  p=0.29; RR 0.94 (95%CI: 0.82-1.07) Apart from an older median age of the 
group with non-ESBL-KP infection, 21.5 (IQR 12.6-67.2) versus 3.1 (IQR 1.1-7.6) 
months, p value <0.001, there were no significant differences on univariate analysis 
between children with polymicrobial and single-organisms KP BSI (see Table 4.5 and 
4.6). Additionally, they were not at greater risk of dying: 25/69 (36.2%) versus 
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CHAPTER FIVE: OUTCOME OF CHILDREN WITH KLEBSIELLA 
PNEUMONIAE BLOODSTREAM INFECTION 
5.1  Clinical complications associated with Klebsiella pneumoniae 
bloodstream infection 
Children with KPBSI experienced a number of organ dysfunction complications that 
affected their outcomes. The following sub-sections summarised respiratory, renal, 
hepatic, and haematological complications. As these complications were on the causal 
pathway to death because of the BSI, they were not analysed as independent risk 
factors in the multivariate model to avoid the problem of co-linearity.  
5.1.1 Respiratory failure in children with and without ESBL-KP 
bloodstream infection 
Of the children, 144 (35.2%) required mechanical ventilatory support at the time of 
the KPBSI. Children with ESBL KPBSI were more likely to develop respiratory failure 
than those with non-ESBL KPBSI, 131/339 (38.6%) versus 13/71 (18.3%), risk ratio 
2.11 [95% CI: 1.27 – 3.51] (see Table 5.1). 
5.1.2 Renal function changes in children with and without ESBL-KP 
bloodstream infection 
Renal dysfunction occurred in 105/410 (25.6%) children if the serum creatinine was 
above the upper limit for age. This was not influenced by whether the KP BSI was 
ESBL-related in 86/339 (25.4%) children or not [19/71 (26.8%) children], p-value= 
0.81: RR 0.95 (95% CI 0.62-1.45) (see Table 5.1).  
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5.1.3 Liver function dysfunction in children with and without ESBL-
KP bloodstream infection  
Hepatic dysfunction, as evidenced by elevated transaminases, occurred in 71/410 
(17.3%) of the children. There was no significant association with ESBL infection, 
62/339(18.3%) children had hepatic dysfunction compared to 9/71(12.7%) children 
with non-ESBL BSI, p=0.26: RR 1.44(0.75-2.77) (see Table 5.1).  
5.1.4 Coagulation disturbances in children with and without ESBL-KP 
bloodstream infection  
Healthcare providers performed coagulation studies on 127 children. Coagulopathy 
was not significantly more common in 66/108 (61.1%) children with ESBL infection 
compared to those 7/19 (36.8%) children with non-ESBL infection, p=0.05: RR 
1.66(95%CI 0.90-3.05). Table 5.1 summarises the various organ dysfunctions in 
relation to ESBL-infection. 
Table 5.1: Prevalence of organ dysfunction in children with ESBL-KP 
bloodstream infection 









p value; RR 
 (95% CI) 
     
Respiratory failure 144/410(35.2) 131/339(38.8) 13/71 (18.3) 0.001; 2.11    
( 1.27-3.51) 




71/410 (17.3) 62/339(18.3) 9/71(12.7) 0.26; 1.44 
(0.75-2.77) 
     
Coagulopathy 73/127 (57.5) 66/108 (61.1) 7/19 (36.8) 0.05; 1.66 
(0.90-3.05) 
RR - risk ratio 
ESBL BSI- 
n/N stratum specific proportions 
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5.2 Mortality 
Over the 6-year period, 123 of the study children died, giving a crude case fatality rate 
of 30% (123/410). The median time to death was 4 days (IQR 1-13 days). There were 
95/123 (77%) deaths occurring within 14 days of positive KP blood culture, and 57 
(46%) children died within 3 days of the positive KP-blood culture (see Figure 5.1 and 
Table 5.2).  
Of the study children, 21 died (i.e. 17.1% of all deaths) on the day the blood culture 
were taken, including two who died on the day of admission to hospital. Community 
acquired-KP infection caused one of these deaths, and the other 20 children had 
nosocomial KP infections. ESBL-producing KP caused 19/ 20 infections. Six untreated 
children died before healthcare providers could initiate appropriate antibiotic 
therapy. 
Figure 5.1: Time to death in 123 children with Klebsiella pneumoniae 
bloodstream infection 
 



























0 10 20 30 40
Frequency
Median time to death:  4d (IQR 1-13) 
                                     ≤ 3d: 57 (46%) 
     ≤ 14d: 95 (77%)  
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Of 123 deaths, 111/339 (32.7%) were ESBL-related compared to 12/71(16.9%) that 
were non-ESBL-related, p=0.008, RR 1.94 (95% CI: 1.13-3.32). Septicaemia was the 
documented cause of death in 90/123 (73.2%) of cases, and pneumonia accounted 
for 13.8% of the mortalities (see Table 5.2). There were 4/21(19.1%) children that 
died in whom the KPBSI was community acquired compared to 119/389 (30.6%) 
deaths in children with healthcare-related KP BSI, p=0.26, RR 1.61 (95% CI: 0.66-
3.93). 
Table 5.2: Time to death in 3 time categories in study children with 
Klebsiella pneumoniae bloodstream infection 
Cause of death          ≤ 3 days
n % n % n % n %
Septicaemia 48 (39) 28 (22.8) 14 (11.4) 90 (73.2)
Pneumonia 6 (4.9) 4 (3.3) 7 (5.7) 17 (13.8)
Other 3 (2.4) 6 (4.9) 7 (5.7) 16 (13.0)
Totals 57 (46.3) 38 (31) 28 (22.8) 123 (100)
Time to death from KP BSI
Totals >14 days 3.1-14 days
Death from septiceamia was most likely to occur within 14 days of the KP BSI, 
76/90(84%) children died compared to non-septicaemia where 19/33 (58%) 
died during the same period; p= 0.002. 
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Table 5.3: Characteristics of children with KP-bloodstream infection who 








Number of children (%) 123/410 (30) 287/410  (70) - 
Median (IQR) age in months 4.4 (1.3-14.9) 5.5  (1.9-16.2) 0.33 
Gender: male: female 61:62 151:136  0.58 
Age <1year (n, %) 88 (71.5) 194 (67.6) 0.43 
Moderate to severely 
underweight-for-age  
78 (63.4) 163 (56.8) 0.21 
HIV-infection 39 (32) 43 (15.0) 0.001 
Unknown HIV status 29 (23.6) 93 (32.4) - 
Chronic underlying medical 
condition 
87 (70.7) 176/287 (61.3) 0.07 
      
Median time to 
bloodstream infection from 
admission (IQR) in days 
8 (4-19) 7 (3-20) 0.48 
      
Median time to death from 
bloodstream infection (IQR) 
in days 
4 (1-13) -  - 
      
Hospitalisation within 
previous 28 days 
58 (47.1) 113/283 (39.9) 0.18 
      
Bloodstream infection 
without clinical focus 
47 (38.5) 159/286 (55.6) 0.002 
n/N: stratum specific proportions; IQR: interquartile range 
 
 
Of all the children who died, 29% (36/123) had no chronic underlying medical 
disorder. At the same time, 32% (39/123) of the children were HIV-infected (see 
Tables 5.3 and 5.4). Chronic gastrointestinal and congenital cardiac conditions were 
present in 10% (13/123) and 12% (15/123) of children respectively. 
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Table 5.4: The chronic medical condition in children that died with 
Klebsiella pneumoniae bloodstream infection 
Chronic underlying medical condition in 
123 children that died 
n % 
Nil 36 29.3 
HIV infection 39 31.7 
Congenital heart disease 15 12.2 
Gastrointestinal 13 10.6 
Neoplasm 5 4.1 
Neurology 4 3.3 
Renal 3 2.4 
Aplastic anaemia 3 2.4 
Tuberculosis 2 1.6 
Metabolic 1 0.8 
Congenital CMV* 1 0.8 
* Cytomegalovirus infection 
5.3 The role of HIV infection in outcome 
Mortality was higher in the HIV-infected group of children compared with those who 
were uninfected. Of the 82/288 (28.5%) children known to be HIV-infected, 39 /82 
(47.5%) died compared to 55/ 206 (26.7%) HIV-uninfected children, RR 1.78 (1.29-
2.45), p=0.001 (see Figure 5.3).  Table 5.5 summarises the outcome of HIV-infected 
children on ART over the study period.  
The proportion of HIV-infected children peaked at 26.7% (23/86) in 2009 with the 
peak of KP BSI cases (86/410) and then reduced to 7.8% (4/51) in 2011.  Of the HIV-
infected group, 41/82 (50 %) children were on antiretroviral therapy (ART) at the 
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time of the KP BSI. In 2006 71.4% (10) of 14 HIV-infected children died, at that time 
14.3% of the 14 children were on ART; mortality in the HIV-infected children with 
KPBSI was high throughout the 6 year study period ranging from 35.3% to 71.4% 
despite the overall trend of improved access to ART. Even when all HIV-infected 
children (4) were on ART, mortality from KP SBI was 50% in 2011.  
Table 5.5: Number and percentages of HIV-infected children on ART who 
lived or died over the study period 
Variable 2006 2007 2008 2009 2010 2011
Number of children with KP BSI 70 50 73 86 80 51
Number of HIV-infected children 14 11 17 23 13 4
% with HIV infection of total  KP BSI 20 22 23.3 26.7 16.3 7.8
% HIV-infected children on ART 14.3 45.5 64.7 47.8 61.5 100
N of HIV-infected children dying per year 10 4 6 12 5 2
% of all HIV-infected children that died 71.4 36.4 35.3 52.2 38.5 50
 
KP BSI: Klebsiella pneumoniae bloodstream infection 
ART: antiretroviral therapy 
%: percentage 
 
The median time on ART prior to the BSI was 19 IQR (8-66) days in the 41 children 
on ART. Five (12.2%) of these children had been on ART for 6 months or longer at the 
time of the KPBSI. Within the HIV-infected group the risk of death was reduced in 
those on ART (14/39 (35.9%) compared to those 25/39 (64.1%) children not on ART; 
p=0.02, RR 0.56(CI 0.34-0.92) (see Figure 5.3). There was 1/ 5 (20%) child who died 
who had been on ART for 6 months or longer compared to 13/36 (36.1%) children 
who died and had been on ART for less than 6 months, p= 0.44.  
The analysis did not show significant links between severe immunosuppression-for-
age and mortality, 21/39 (53.9%) children with severely immunosuppressed CD4 for 
age who died compared to 21/43(48.8%) children who were severly 
immunosuppressed and lived, (p=0.65; RR 1.10 (0.70-1.75). The same was true for 
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those 26/39 (66.7%) children with severely immunosuppressed absolute CD4 count 
for age who died compared to 29/43 (67.4%) children who lived, p=0.94; RR 0.98 
(0.61-1.59). However, the timing of the CD4 lymphocyte testing was not uniform in 
that the healthcare providers collated results within the preceding 3-month period of 
the BSI. In the presence of HIV disease, mortality was not significantly influenced by 
moderate or severe underweight-for-age status, 28/39 (71.8%) children died 
compared to 33/43 (76.7%) children who lived, (p= 0.61; RR 0.88 (CI 0.54-1.43). 
 
Figure 5.3: The number of HIV-infected children with KPBSI and the 
proportion on ART over the study period 2006-2011 
 
KP BSI: Klebsiella pneumoniae bloodstream infection 
ART: antiretroviral therapy 
 
 
5.4 The cause of death 
Healthcare providers recorded the cause of death for 122 children. In one child 
admitted with severe burn injury, the death was unexpected and occurred in the burn 
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Table 5.6: Cause of death in 123 children with Klebsiella pneumoniae 
bloodstream infection 
Cause of death n Percentage 
Septicaemia 90 73.2 
Pneumonia 17 13.8 
Multi-organ dysfunction syndrome 4 3.3 
NEC 3 2.4 
Neoplasm 2 1.6 
Hepatitis 1 0.8 
Peritonitis 1 0.8 
Volvulus 1 0.8 
Tyrosinaemia, liver failure 1 0.8 
Congestive cardiac failure 1 0.8 
Bacterial endocarditis 1 0.8 
Unknown(not recorded, burns patient) 1 0.8 
KP: Klebsiella pneumoniae  
NEC: necrotising enterocolitis 
5.5  Post-mortem findings  
 Of the 123 study children that died, 15 had post mortem examinations. Table 5.7 
summarises the main necropsy findings. Necrotising tissue breakdown was a 
common post mortem finding.  
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Table 5.7: Key post mortem features in 15/123 hospitalised children with 
Klebsiella pneumoniae bloodstream infection 
Post mortem feature n Percentage (%) 
Multi-lobar necrotising pneumonia 15 100 
Disseminated intravascular coagulopathy 8 53.3 
Skin excoriation and ulceration 8 53.3 
Acute adrenal haemorrhage 7 46.7 
Acute tubular necrosis 6 40 
Abscess formation 5 33.3 
Necrotising enterocolitis 5 33.3 
Necrotising oesophagitis 4 26.7 
Septic pulmonary emboli 4 26.7 
Peritonitis with abundant pus 2 13.3 
 
The Tables 5.8 and 5.9 describes characteristics of 15 children who died and their 
post mortem findings. All 15 children had evidence of bronchopneumonia at post 
mortem. Thymic involution was evident in 14 of the 15 children. All 15 children died 
within 6 days of developing KP BSI. 
Acute tubular necrosis (ATN), disseminated intravascular coagulopathy (DIC), and 
adrenal haemorrhage were prominent additional features. A common finding was 
necrotising inflammation, indicative of tissue destruction. KP was positively 
identified in 8/15 lung specimens but was not mentioned in the post-mortem reports 
of the other seven children. In one in these seven children, disseminated CMV 
infection was present. This child was HIV-uninfected. Another child, with KP 
confirmed at post-mortem, also had evidence of Pneumocystis jirovecii (PJP) and 
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5.6 Laboratory results in association with crude mortality  
Mortality increased significantly when there was evidence of organ failure or 
dysfunction concomitant with the BSI. Table 5.10 summarises these data. Mortality 
was higher in 58/123 (47.2%) children wih renal dysfunction compared to 47/287 
(47.2%) children with renal dysfunction who lived, p <0.0001: RR 2.88 (95% CI 2.09-
3.97). In the presence of hepatic dysfunction, 49/123 (39.8%) children died 
compared to 22/287 (7.7%) children who lived, p<0.0001: RR 5.20 (95% CI 3.29-
8.20), on univariate analysis. 
Table 5.10: The association of organ dysfunction in children with KP 
bloodstream infection and mortality 





 n=123 (%) 
p value; RR  



































0.001;           
1.77 (1.23-2.55) 
RR: risk ratio  
 
5.6.1 Haematological changes 
Children who died had a significantly lower mean haemoglobin of 9.19 g/dl compared 
to those who survived; survivors’ mean haemoglobin was 9.94 g/dl, p value=0.001. 
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Their median MCV did not differ. The median band, neutrophil, and lymphocyte 
counts did not differ in the two groups of children; however, the median platelet count 
of 54 x 109/L was significantly lower in the children who died, p=<0.0001.  
Infective marker CRP was significantly higher in children who died with a median 
value of 142(IQR 82-206) mg/l. This is in contrast to the median value of 79 (IQR 27-
186) mg/l in those who lived, p= 0.001. Procalcitonin (PCT) levels did not differ 
significantly (see Table 5.11).  
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Table 5.11: Comparison of baseline haematological indices in children with KP 
bloodstream infection who survived or died  
Hb: haemoglobin 
WBC: white blood cell 
MCV: mean corpuscular volume 
IQR: interquartile range 
SD: standard deviation  
 
5.6.2 Analysis of baseline haematological cell line changes and 
mortality 
Red cell line reduction, as represented by anaemia, was the most common single 
cytopaenia in children who died or survived (see table 5.12). The prevalence of 
leukopaenia was not significantly different in children who died; however, isolated 
thrombocytopaenia as well as pancytopaenia were more common in children who 
died. The bicytopaenias, anaemia with thrombocytopaenia, anaemia with 
Mean Hb (SD) 9.71 (± 2.18) 407 9.94(2.08) 285 9.19 (2.32) 122 0.00
Median MCV (IQR)fL 84 (78-89) 407 84 (78-89) 285 84 (78-90) 122 0.82
Median wbc (IQR) x 109 11.7 (6.24-20.09) 407 11.7 (6.6-19.9) 285 12.25 (3.69- 22.63) 122 0.92
Median band count (IQR) x109 1.50 (0.43-4.16) 354 1.44 (0.45-3.7)  238 1.63 (0.29-4.7) 116 0.58
Percent band count (IQR) 14 (5-27) 243 13 (5-27) 238 16 (6-28) 116 0.58
Neutrophil count (IQR) x109 4.66 (1.48-10.32) 355 5.3 (1.86-10.12) 240 3.38  (0.45-11.29) 115 0.25
Lymphocyte count (IQR) x109 2.64 (1.27-4.37) 354 2.65 (1.37-4.35) 239 2.62  (1.04-4.55) 115 0.81
Platelet count (IQR) x 109 113(34-306) 405 154 (52-356) 283 54(18-160) 122 <0.0001
C reactive protein (IQR) mg/l 108 (38-194) 203 79 (27-186) 137 142 (82-206) 66 0.00
Procalcitonin (IQR) ng/ml 15.25 (1.9-41.7) 106 7.35 (1.6-41.7) 70 22.75 (7.6-41.3) 36 0.16
n p valueVariable All children (n=410) n n Died (n=123)Alive (n=287)
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leukopaenia, and leukopaenia with thrombocytopaenia were all more common in the 
group that died (see Table 5.12).  
Table 5.12: Comparisons of haematological cytopaenias in children who 
lived or died  
 
5.7 Univariate analysis of risk factors of all children who died 
Table 5.13 summarises crude risk factors associated with death. KPBSI without a 
focus was associated with a lower mortality risk in 159/286 (55.6%) than in those 
patients with an identified focus of infection [47/122 (38.5%); p=0.002; RR 0.61(95% 
CI 0.45-0.84)]. Factors that on univariate analysis were associated with increased 
mortality included ESBL KP BSI, HIV infection, being in the PICU at the time of the BSI, 
KPBSI requiring admission to PICU, and the presence of excoriated skin (see Table 
5.13).  
  
All Children RR (95% CI) p value 
Cell line n    (%) n    (%)
Anaemia (Hb<11) 196 (68.3) 94  (76.4%) 1.11 (0.99-1.27) 0.10
Leukopaenia 62 (21.8%) 34  (27.9%) 1.28 (0.89-1.84) 0.18
Thrombocytopaenia 135  (47.7%) 88  (72.1%)  2.11 (1.50-2.98) <0.001
Pancytopaenia 34  (12%) 28  (23%) 1.65 (1.20-2.29) 0.00
Thrombocytopaenia, no pancytopaenia 101  (35.2%) 60 (48.8%) 1.38 (1.09-1.76) 0.01
Anaemia with Thrombocytopaenia 98  (34.2%) 73  (59.4%) 2.04 (1.51-2.76) <0.001 
Anaemia with Leukopaenia 49 (17.1%) 32  (26.0%) 1.43 (1.04-1.97) 0.04
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5.8 Multivariate analysis of children who died 
In the multivariate analysis, HIV infection and excoriated skin remained significant 
risk factors for death as did patients either in the PICU at the time of the KPBSI or 
needing PICU admission. Children with KP BSI without a clinical focus were less likely 
to die. The group of children with excoriated skin included those with burn wounds 
as a form of extreme excoriated skin. If the children with burn wounds were excluded 
from the analysis, skin excoriation remained a significant risk factor for mortality 
[p=<0.0001, RR 1.76 (1.33-2.33)]. 
5.8.1 Illness-specific factors and mortality 
In the crude analysis, children without a clinical focus of infection had a lower risk of 
death. This is in opposition to those who had advanced organ involvement such as 
pneumonia, peritonitis, or NEC (see Table 5.14). 
Table 5.14: Illness specific factors and unadjusted relative risk of death in 
410 hospitalised children with bloodstream Klebsiella pneumoniae 
infection 
Illness-specific factors Alive 
n/N (%) 
Died  
n/N   (%) 
Univariate analysis 
p-value;                  RR (95% CI) 
BSI without a focus  159/286 (55.6) 47/122   (38.5) 0.002;                0.61 (0.45-0.84) 
Pneumonia 74/285 (26) 48/122   (39.3) 0.007                 1.52 (1.13-2.04) 
Peritonitis 8/285 (2.8) 12/122   (9.8) 0.003;                2.11 (1.43-3.12) 
Necrotising 
enterocolitis 
9/286 (3.2) 11/123   (8.9) 0.01;                  1.91 (1.25-2.93) 
RR: risk ratio 
BSI: bloodstream infection 
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5.9 Complications associated with mortality 
Children whose BSI was associated with complications had a higher risk of mortality 
as compared to those whose BSI was uncomplicated (see Table 5.15). 
Table 5.15: Clinical complications and relative risk of death in hospitalised 
children with bloodstream Klebsiella pneumoniae infection 
Complication Alive Died
n/N (%) n/N (%) RR (95% CI)  p-value
Respiratory failure 56/287 (19.5) 88/123(71.5) 4.64(3.32-6.49) < 0.001
Renal injury 47/287 (16.4) 58/123 (47.2) 2.59 (1.97-3.42) < 0.001
Hepatic dysfunction 22/287 (7.7) 49/123(39.8) 3.16 (2.45-4.08) < 0.001
Septic shock 48/284 (16.9) 91/122(74.6) 5.64 (3.96-8.02) < 0.001
Coagulopathy 21/53 (39.6) 52/74(70.3) 1.75 (1.23-2.49) 0.001
Patient needed to go to PICU 47/287 (16.4) 37/123 (30.1) 1.67 (1.23-2.26) 0.002
Univariate RR
RR: relative risk 
PICU: paediatric intensive care unit 
 
Crude mortality included all children with KPBSI who died including 28/123 (22.8%) 
who died more than 14 days after the BSI, implying that these deaths were not 
associated with the BSI. Analysis of deaths occurring within the first 14 days of BSI 
had a higher chance of identifying risk factors for KPBSI. 
5.9.1 Factors associated with mortality within the first 14 days of 
KPBSI 
An exploratory analysis of factors associated with mortality was unable to distinguish 
any difference in children who died within the first 14 days of the KPBSI from those 
who died later (see Table 5.16).  
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Table 5.16: Factors associated with mortality <14days of KP bloodstream 
infection  
Risk factors for mortality <14 days 
( n=95 (77.2%)) 
Univariate analysis 
p-value;    RR (95% CI) 
ESBL-KP bloodstream infection 0.10; 1.36 (0.83-2.21) 
Age (infant vs. >1y) 0.33; 1.11 (0.88-1.41) 
Gender (female:male) 0.36; 0.91 (0.75-1.11) 
Moderate or severe underweight 0.74; 1.04 (0.84-1.27) 
Hospitalisation within previous 28 
days 
0.6; 1.05 90.87-1.27) 
HIV-infection 0.67; 0.95 (0.75-1.20) 
Concomitant chronic medical 
condition 
0.13; 0.85 (0.71-1.02) 
Patient in the PICU at time of B/C 0.33; 0.90 (0.72-1.13) 
Patient needed to go to PICU at the 
time of KP bloodstream infection 
0.50; 1.07 (0.88-1.31) 
Bloodstream infection without source 0.33; 0.90(0.73-1.12) 
Time to effective antibiotic 0.13; 0.85 (0.71-1.02) 
Excoriated skin 0.55; 1.06 (0.88-1.29) 
ESBL-KP: Extended-spectrum β-lactamase producing-Klebsiella pneumoniae 
RR: risk ratio  
PICU: paediatric intensive care unit 
B/C: blood culture 
5.9.2 Factors associated with mortality within the first 3 days of 
KPBSI (early KPBSI deaths) 
With the 57 (46.3%) children who died within 3 days of the KP BSI, the mean time to 
death in this group was 1 (SD ± 0.93) day. Twenty-one children died on the day 
healthcare providers took the blood culture. Two children died on the day of hospital 
admission: one of them had a community-acquired ESBL-KP infection and the other 
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had healthcare-associated ESBL-infection; the HIV status was unknown in both 
children. 
Of the children dying within three days of KP BSI, 23 (41%) presented with diarrhoeal 
disease, 15 (27%) had pneumonia, 13 (23%) had kwashiorkor, and 9 (16%) were 
thought to have sepsis. Univariate analysis did not identify specific risk factors 
identified in this group of children that died within 3 days of the positive blood 
culture. Those who were already in the PICU setting prior to the BSI were less likely 
to die within 3 days of the infection; thus, researchers could not generate a 
multivariate analysis (see Table 5.17).  
Table 5.17: Factors associated with early (patient died within 3 days of KP 
bloodstream infection) mortality 
Risk factors for early (death≤ 3days) 
mortality (n=57 (46.3%)) 
Univariate analysis 
p-value;    RR* (95% CI) 
ESBL-KP bloodstream infection 0.34;    1.43 (0.63-3.26) 
Age (infant vs. >1y)   0.48;       0.86 (0.58-1.28) 
Gender (female: male) 0.92;     0.98(0.67-1.44) 
Moderate or severe UWFA 0.75;    1.07 (0.71-1.59) 
HIV-infection 0.59;    1.11 (0.75-1.64) 
Patient in the PICU at time of B/C* 0.02;     0.57 (0.34-0.96) 
Patient needed to go to PICU at the time of 
KP bloodstream infection 
0.13;    1.35 (0.93-1.97) 
Bloodstream infection without source 0.83;      0.96 (0.64-1.43) 
Time to effective antibiotic 0.27;    0.79 (0.53-1.18) 
Excoriated skin 0.66;      1.09 (0.74-1.60) 
ESBL-KP: Extended-spectrum β-lactamase producing Klebsiella pneumoniae 
RR: risk ratio 
PICU: paediatric intensive care unit 
B/C: blood culture 
UWFA: underweight-for-age 
* p-value ≤0.05 
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CHAPTER SIX: DISCUSSION 
This hospital-based retrospective study helped describe the emerging problem of 
multi-drug resistant Klebsiella pneumoniae (KP) bloodstream infections (BSI) at Red 
Cross War Memorial Children’s Hospital (RCWMCH). The study aim was broken down 
into six specific objectives. (1) The description of the presentation of Klebsiella 
pneumoniae (KP) bloodstream infections (BSI) at RCWMCH over a 6 year period. (2) 
The description of the spectrum of risk factors associated with ESBL- KP BSI. (3) The 
comparison of the healthcare-related- and community-acquired KP BSI. (4) The 
evaluation of the antibiotic susceptibility patterns of Klebsiella pneumoniae isolates 
and the antibiotic selection and response to KP-bloodstream infections.  (5) The 
evaluation of factors associated with inpatient mortality. Finally, (6) the assessment 
of the outcome of KP BSI in HIV-infected and uninfected children. This chapter 
contains a discussion of each of these objectives. Thereafter, there is an analysis of 
limitations and strengths of the study.  
6.1 Objective one: Presentation of KP BSI at Red Cross War 
Memorial Children’s Hospital over a 6 year period 2006-2011 
6.1.1 Patient profile 
The study contained a skewed age distribution documenting that infants were the 
most affected age group. The median age of the children was 5.0 months, interquartile 
range (IQR) 2 to 16 months, with 68.9% (282) being less than 12months old. In the 
only other large published paediatric case series on KP BSI that involved 57 American 
children, infants were also the most vulnerable age group, in that study-68% 
(n=38/57) of the children were less than 12 months (Bonadio, 1989). In the Korean 
study by Kim et al., the mean (±SD) age of the study children with ESBL-producing 
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Escherichia coli (ESBL-EC) and ESBL-producing KP BSI (ESBL-KP) was 4.58 (±5.02) 
years (Kim et al., 2002). Zaoutis et al., reported a median age (IQR 0-11) of 2 years in 
their study on children with ESBL-EC and ESBL-KP BSI (Zaoutis et al., 2005). In a 
Kenyan study on paediatric community-acquired BSI, 37% (6137/16 570) of children 
were less than 12 months (Berkley et al., 2005). In that study, Klebsiella spp. made up 
only 3.2% (36/1132) of the community-acquired bloodstream isolates. Possibly the 
major reason for this observation is that a high proportion of all children admitted to 
RCWMCH are under 12 months of age, in two 12-month-long surveys conducted in 
2007 and 2010 in one of the general medical wards showed that 66.7% (IQR: 59 – 76) 
and 62.1% (IQR: 53.9 – 69.2) respectively of all admitted children were < 12 months 
of age (Weakley et al., 2009 and B Eley, personal communication, 29th July 2015)  
Another important contributory reason may be that young children, particularly 
infants, are not fully immunocompetent and may be susceptible to infectious diseases 
including KP BSI; this may also contribute to the delayed diagnosis of sepsis (Clapp, 
2006).  
The prevalence of child malnutrition in the less than 5-years age group in sub-Saharan 
Africa, defined as < -2 WFA z-score, was 8.7% in 2012. In South Africa, the estimate 
was at 9%. (UNICEF, New York; WHO, Geneva; The World Bank, Washington, DC; 
2012). A National Foods Consumption survey of 2005 that found that 1 in 5 South 
African children were stunted and 1 in 10 were UWFA (National Food Consumption 
Survey Fortification Baseline (NFCS-FB-I) South Africa, 2005). The present study 
however documented a high prevalence of underweight in hospitalised children. In 
this study, 241 (58.8%) children were moderately to severely underweight-for-age. 
Of these, 163 (39.8%) children were severely underweight-for-age (UWFA). Children 
with with moderate- or severe- underweight-for-age were at higher risk of having 
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ESBL-KP (209/339, 61.7%) infection compared to those with non-ESBL infection 
(32/71, 45.1%); p=0.01. Malnutrition is associated with widespread micronutrient 
deficiencies, immune dysfunction, and susceptibility to infectious complications 
(Beisel, 1996).  
Documentation showed HIV status in 70% (288/410) of study children. Of the 
children, 206 (50.2%) were HIV negative and 82 (20%) were HIV-infected. This is 
important information given the burden of HIV disease in Sub-Saharan Africa. It 
allowed unique insight into not only the effect of HIV infection on KP BSI but also the 
effect that frequent contact with the healthcare environment had on the development 
of healthcare-related KP BSI. UNAIDS estimate that there are some 3 million children 
aged 0-14 years living with HIV in sub-Saharan Africa; the prevalence in South Africa 
is estimated at 410 000 children (UNICEF, 2013). The high prevalence of HIV infection 
shown in the study children likely reflected the degree of immunosuppression that 
characterises paediatric HIV disease and the susceptibility to BSI and need for 
hospitalisation. Consistent with this, Le Roux et al. reported on 47 BSIs occurring in a 
cohort of 125 HIV-infected children (Le Roux et al., 2011). Furthermore, in the present 
study, HIV infection was associated significantly with ESBL infection compared with 
non-ESBL KPBSI on univariate analysis (p =0.001, RR (RR 1.17, (95% CI 1.08-1.26)). 
Only 3/82 (3.7%) HIV-infected children had non-ESBL infections.  
6.1.2 Clinical site of infection at the time of the KP BSI 
There were differences noted at presentation in children with and without ESBL-
related KP BSIs at the time of the BSI. ESBL-KP infections were more common in 
children who had pneumonia as their primary manifestation (p=0.03; RR 1.65 (95%CI 
1.00-2.70)). Children with non-ESBL-KP infection were less likely to have an 
identifiable clinical focus (p= 0.004; RR 0.72 (95% CI 0.59-0.88)). Other clinical events 
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were seen at the time of the blood culture including peritonitis, necrotising 
enterocolitis (NEC), soft tissue and wound infections, urinary tract infections (UTI), 
septic peripheral drip sites, and central vascular catheters. These did not significantly 
link to ESBL-infection. In contrast, Kim et al. found that 42% of their study children 
with non-ESBL Gram-negative BSI had clinical foci of infection compared to 27% of 
those with ESBL-BSI; however, these rates did not reach statistical significance, 
p=0.07 (Kim et al., 2002). Although 50.2% (206/410) of the children in the present 
study did not have a definable clinical focus at the time of the BSI, when found this 
was typically in the lungs- 29.7% (121/410) of the children with a clinical diagnosis 
of pneumonia. In a parallel study on Staphylococcus bacteraemia at the same 
institution, 33% (110/337) of children had no identifiable source and, where 
identified, the lungs were the most common focus in 72/337 (22%) children (Naidoo 
et al., 2013). Other paediatric studies of Gram-negative BSIs including KP described 
bacteraemia in the absence of a clear clinical focus; the prevalence was 68% in one 
study (Levy et al., 1996).  
The infection was nosocomial or healthcare-associated in 389/410 (95%) children 
and community-acquired in 21 (5%). The striking scarcity of the resistant ESBL-form 
from the community and the predominance of nosocomial acquisition of the ESBL-KP 
is consistent with other reports (Levy et al., 1996; and Al-Hasan et al., 2011). 
The inflammatory process involved in an episode of BSI is complex.  Unlike the child 
coming in from home with the CA BSI where the BSI is already manifest by virtue of 
presentation at a healthcare facility, there may be delays in recognition of the BSI in 
the child with a HRF-BSI. In addition children may have non specific signs of sepsis 
leading to delays in recognition especially if they have been hospitalised with another 
clinical complaint. In the present study 206 (50.2%) of all children did not have a 
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definable clinical focus of infection and, 30% (126/410) did not experience fever at 
the time of the positive blood culture; ineffective empiric therapy would also lead to 
further delays. In a meta-analysis comparing the mortality of adults and children with 
ESBL-related and non-ESBL-related Enterobacteriaceae BSI, Schwaber and Carmeli 
described significant association between ESBL production by Enterobacteriaceae 
and delays in effective therapy (Schwaber and Carmeli, 2006). The present study 
found the median hospitalisation time from admission to non-ESBL BSI (3days) was 
significantly shorter than that for the acquisition of ESBL-BSI (9days), p<0.0001, RR 
1.45 (1.21-1.74) but was limited by the fact that time to antibiotic therapy was not 
known because of incomplete documentation in the clinical case files.   
6.1.3 Changes in laboratory parameters at the time of the KP BSI 
In keeping with the high prevalence of malnutrition in the study children, 71% 
(290/407) of patients had normocytic normochromic anaemia at the time of the 
bacteraemic event. The mean haemoglobin was 9.7 g/dl SD± 2.18 and the median 
mean corpuscular volume (MCV) was 84 (IQR 78-89) femtolitres. However, anaemia 
was not more prevalent in children who were moderately or severely UWFA 
compared with those with normal weight-for-age, p=0.75; RR 0.97 (95%CI 0.81-1.16). 
Furthermore the study also showed that anaemia was not more prevalent in 183/263 
(69.6%) children with a chronic underlying condition compared to 107/147 (72.8%) 
children without, p= 0.49. In contrast, a National Foods Consumption Survey of 2005 
found that one third of South African children aged 6-71 months were anaemic 
(National Food Consumption Survey Fortification Baseline (NFCS-FB-I) South Africa, 
2005).  
Children with ESBL-KP infection had a lower mean haemoglobin, 9.57 g/dl versus 
10.5g/dl, p=0.003, and lower median platelet counts, 98 (IQR 31-284) versus 183 
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(IQR73-382), p=0.003, compared with children with non-ESBL KP BSI. Their median 
white blood cell (WBC) counts and percentage band counts did not differ significantly. 
Thrombocytopaenia is commonly seen in bacteraemic processes with this commonly 
due to a consumptive process (Goyette et al., 2004). It is not clear why an ESBL-KP 
BSI associated with a lower platelet count compared with having a non-ESBL 
infection. Particularly since the median values of the two pro-inflammatory markers 
C-reactive protein (CRP) and procalcitonin (PCT) were elevated in both groups, 108 
(IQR 38-194) and 15.25 (IQR 1.9-41.7) respectively. Elevated levels of CRP >80 mg/l 
and PCT >2ng/ml are commonly regarded as better cut-off values for identifying 
invasive bacterial infections as opposed to lower levels that may sometimes be seen 
with viral illnesses (Van den Bruel et al., 2011). In the children tested, 59.1% 
(120/203) and 74.5% (79/106) had levels of CRP and PCT above these values; this 
was uninfluenced by the ESBL status of the KP isolate. 
Coagulation disturbances were evident in 17.6% (73/127) of the tested children; 
61.1% (66/108) of those with ESBL-KP infection had evidence of disturbed 
coagulation compared with 36.8% (7/19) with non-ESBL infection, p=0.05: RR 
1.16(1.00-1.37). Coagulation disturbances may reflect the degree of clinical 
complications that can be associated with invasive Gram-negative infections. It is 
unclear why having a resistant organism predisposes to inflammatory mediated 
coagulation disturbances but may rather reflect treatment delays. For example the 
study documented that 94.3% (66/70) of children with non-ESBL BSI received an 
appropriate empiric antibiotic compared with 74.5% (241/328) who had ESBL-KP 
BSI, p=0.0002, this may imply treatment delays. However, this is only speculation 
because the study did not document the time delay between drawing the definitive 
blood culture and the introduction of the empiric antibiotic. 
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6.2 Objective two: Spectrum of risk factors for ESBL-acquisition 
Using generalised linear modelling with Poisson distributions, the adjusted analysis 
showed significant risk factors for the acquisition of ESBL-KP BSI. Risk factors 
included cephalosporin exposure in the preceding 12 months prior to the KPBSI, HIV 
infection and more than 3 days IV fluid infusions prior to the KP BSI.  
Prior cephalosporin exposure appears to be a common risk factor described in several 
paediatric studies involving the broader group of Enterobacteriaceae BSIs. As in the 
present study, Zaoutis et al. in the USA and Kim et al. in Korea showed that 
cephalosporin exposure significantly increased the risk of ESBL acquisition, p= 0.002; 
OR, 5.82 (95% CI ,1.92–17.68) and p = 0.001; OR, 5.56( 95% CI, 1.9 to 16.0) 
respectively. Tsai et al. in Taiwan reported this association with cephalosporin 
exposure as significant in neonates, and Ariffin et al. in Malaysia reported this as well 
as in children with febrile neutropaenia and underlying oncological malignancies 
(Ariffin et al., 1999; Tsai et al., 2014).  
Underlying renal disease and duration of total parenteral nutrition were further 
significant neonatal risk factors for the development of resistance in Gram-negative 
BSI (Samanta et al., 2011; Tsai et al., 2014). Kim et al. also reported prior 
hospitalisation and admission to PICU within the previous month in their study (Kim 
et al., 2002). In the present study, these two factors did not seem to be significant. 
Certain unique factors included in the adjusted multivariate model may have 
influenced this.  
There were several factors described in the present study that were notably different 
from those described in adults and children in developed countries. These factors 
included HIV-infection and duration of intravenous (IV) fluid infusions for longer than 
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3 days prior to the BSI that were associated with the development of ESBL-Klebsiella 
pneumoniae (ESBL-KP) BSI infections. No other paediatric studies have specifically 
described KP BSI in HIV-infected children.  
The issue of prolonged intravenous fluid infusions as a risk factor for ESBL-KP 
infection could include many possible reasons. For instance, the risk could relate to 
contamination of the cannula at or following intravenous insertion, contamination of 
the administration sets, and a break in protocol of ensuring sterility when changing 
administration sets. The risk could be due to contamination of intravenous fluids 
when healthcare providers use lines for other functions such as administering 
intravenous drugs or the practice of not changing the administration sets after 
specified periods, particularly in those who have spent long periods in hospital.  
Koerner et al., who implicated improper infusion preparation and irregular staff 
changes, previously described outbreaks of septicaemia from gram-negative-
contaminated intravenous infusions in cardiology patients (Koerner et al., 1997). 
Another case series from Mahatma Gandhi Memorial Hospital, a public neonatal unit 
in KwaZulu-Natal, involved 26 neonates with CVPs and intravenous fluid infusions. 
An infection control examination identified KP-contaminated TPN solutions, solutions 
that were sterile on opening but accessed multiple times against procedural 
guidelines by repeated needle insertion to minimise waste. The mortality rate was 
extremely high at 85% (Moodley et al., 2005). None of these other studies have shown 
what the present study has shown in a multivariate model i.e., intravenous 
cannulation to be a significant risk factor for ESBL-acquisition.  The significance may 
simply reflect poor infection control measures.  
 An environmental inspection at RCWMCH’s short stay unit during a one of the 
diarrhoeal seasons did not find that any surface-colonisation with KP. Although there 
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was no specific testing of any flowing intravenous infusions, it is plausible that this 
mechanism of infection may be more common than commonly thought in wards that 
are overcrowded and under-resourced. In these situations, work-related pressures 
facing the ward nurses do not allow for full compliance with infection control 
measures. One should also acknowledge that the point of entry through the skin of an 
intravenous cannula remains an area of broken skin, and gut pathogens could thus 
contaminate or colonise this localised loss of skin integrity. This mechanism may be 
important in any hospitalised children requiring intravenous cannulae for any length 
of time. 
HIV infection was also a significant risk factor for the infection with resistant KP, p-
value 0.01: RR 1.12 (95% CI 1.02-1.22); there were 79/82 (96.3%) HIV-infected 
children with resistant KP compared to 3/82 (3.7%) with non-ESBL KP. There may be 
several reasons for this. HIV-infected children are in frequent contact with the 
healthcare system, require more hospitalisations than HIV-uninfected children 
require, and are prone to infectious complications by virtue of their 
immunosuppression. For these reasons, they may easily become colonised with 
resistant organisms and still be vulnerable despite antiretroviral therapy (ART). 
Colonisation may have important implications for the development of nosocomial 
BSIs in children. In one study, nasopharyngeal aspirate (NPA) specimens from 167 
HIV-infected South African children attending a central hospital outpatient clinic 
showed that about 15% (n=32) of children were colonised with Enterobacteriaceae 
with 50% being ESBL producers (Cotton et al., 2008). It was not known which patients 
in the present study were colonised with KP or any other pathogens as rectal swabs 
or stool cultures were not routine on admission.  
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6.3 Objective three: Comparison of healthcare related and 
community-acquired KPBSI 
In this study, the adjusted analysis showed that children with healthcare-related KP 
BSI were more likely to have ESBL-KP BSI, a concomitant chronic medical condition 
or be in the PICU at the time of the KP BSI. It is evident that BSI with KP is most likely 
a nosocomial event. Most of the children, 95%, had healthcare risk factors; the 
infection was nosocomial or healthcare-associated in 389 children and community-
acquired in only 21 (5%). Other studies also strongly suggest that this problem of KP 
BSI is a product of the healthcare environment. Reddy et al. showed that Klebsiella 
spp. caused 2.8% of the BSI caused by Enterobacteriaceae in their meta-analysis of 
community-acquired infections across 22 studies (Reddy et al., 2010). Berkley et al., 
from Kenya, reported that KP ranked ninth out of ten in the causative aetiology of 
community-acquired BSI in 1094 Kenyan children (Berkley et al., 2005). In another 
Kenyan paediatric study, Aiken et al. reported that KP caused 20% (43/353) of 
nosocomial BSI but only 2% (37/1590) of the community-acquired infections. 
The high prevalence of a concomitant chronic medical condition in 262 (64%) 
children indicated high exposure to the health system and that the problem of KPBSI 
is a healthcare related one. Consistent with the present study, an American paediatric 
study reported that 91% of children with nosocomial or healthcare-associated Gram-
negative BSI were more likely to have an underlying medical condition compared to 
32% with community-acquired BSI , p<0.001(Al-Hasan et al., 2011). Furthermore, 
they may also indicate that the carriage of these resistant strains is prolonged. 
Researchers have shown this in several studies including that by Löhr et al. where the 
median duration of faecal carriage in 51 infants discharged from a neonatal intensive 
care unit was 12.5 (IQR 9-17.5) months, with the longest time of 23.5 months (Löhr 
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et al., 2013). Whilst septic shock may place children into the PICU environment, time 
spent among critically ill children in the PICU may more commonly predispose them 
to invasive nosocomial infections. This may happen because of supportive procedures 
such as mechanical ventilation, central venous catheterisation, urinary 
catheterisation, invasive monitoring, and invasive surgery.  
Children admitted with community-acquired KP BSI were significantly younger. For 
these, the median age was 1.5 (IQR 0.7-3.8) months compared with 5.5 (IQR 1.9-16.2) 
months in those with healthcare-related KP BSI. This may relate to the susceptibility 
to serious bacterial infections including KP in very young infants with immature 
immunity brought into the healthcare environment (WHO, 1999). There were 7 
(1.7%) cases of community-acquired ESBL-KP BSI - confirmimg that the resistant 
organism was present in the community during the study period. 
6.3.1 Haematological differences in children with nosocomial versus 
community-acquired KPBSI 
At the time of the KP BSI, children with healthcare-associated risk factors (HRF) had 
a significantly lower mean haemoglobin value at 9.65 ±2.18 g/dl than 10.6 ±1.89 g/dl 
seen in children with community-acquired KP BSI, p-value=0.02. Whilst the median 
WBC and percentage band counts did not differ significantly, children with HRF had a 
lower median platelet count of 103 (IQR 32-288) x109/l compared with 350 (IQR 193-
659) x109/l seen in those children those whose infection was community-acquired, p-
value= 0.0001. The anaemia witnessed in children with HRF may reflect a number of 
processes such as marrow suppression that is commonly seen in sick children or may 
even be iatrogenically-induced from repeated venesection. Thrombocytopaenia likely 
reflects a consumptive process that frequently accompanies serious Gram-negative 
BSIs and may be more evident in hospitalised children because of delays in 
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recognising the onset of the infection as other processes may be occurring 
concomitantly. 
6.3.2 Differences in mortality in children with healthcare-related KP 
BSI compared with community-acquired KP BSI 
There was no significant difference in the mortality risk or median time to death from 
the time of the positive KP blood culture in children with HRF compared to those with 
community-acquired BSI. In contrast, Levy et al. reported that hospital-acquired 
Gram-negative bacteraemia accounted for 48.5% of 374 episodes in an Israeli 
paediatric study and that mortality was higher in those with nosocomial BSI 
compared with community-acquired BSI, 23% versus 11%, p-value=0.006 (Levy et 
al., 1996). In a Kenyan study Aiken et al. reported that the case fatality rate in the 
community-acquired group was less than half of that in those with nosocomial BSI, 
24% versus 53% (Aiken et al., 2011). BSI with KP, regardless of whether healthcare-
related or community-acquired, are serious events and as this study has shown the 
clinical outcome can be identical. 
6.4 Objective four: Antibiotic susceptibility patterns of Klebsiella 
pneumoniae isolates and the antibiotic selection and response to KP-
bloodstream infections 
6.4.1 Treatment considerations for children with community 
acquired (CA) KP BSI 
Bloodstream infections with KP, regardless of whether ESBL-associated or not, are 
serious events. As this study showed, many children died and or experienced adverse 
complications. Therefore, empiric antibiotic choices have important implications for 
patient survival, and healthcare providers should make choices using the best 
available evidence-based knowledge. The South African Department of Health 
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hospital level paediatric guidelines recommend ceftriaxone for infants and children 
to cover community acquired sepsis (DOH SA, 2013) whereas the RCWMCH Antibiotic 
guidelines recommend a combination of ampicillin and gentamicin (Nuttall et al., 
2012). The intention for these recommendations is to provide cover for both common 
Gram-positive organisms and common Gram-negative organisms. This study allowed 
some insight into what empiric antibiotics were appropriate for KP BSI at RCWMCH, 
albeit a single pathogen. 
6.4.2 Treatment considerations for children with healthcare-related 
KP BSI 
Whenever a patient develops systemic symptoms due to a suspected hospital 
acquired bacterial organism, it is traditional practice to start with broad cover after 
appropriate investigations to ensure appropriate antibiotic cover for the likely 
pathogen. When cultures results become available, the healthcare provider would de-
escalate to an appropriate single agent. One should remember that ESBL- producing 
KP and Escherichia coli are just two of several resistant hospital-acquired organisms 
threatening hospitalised children. Other significant organisms at RCWMCH include 
methicillin resistant Staphylococcus Aureus (MRSA), multi-drug resistant (MDR) 
Pseudomonas Aeruginosa, and resistant Acinetobacter spp. Individual patient risk 
factors should be carefully considered and an appropriate strategy by a focused body 
involved in the individual patient’s care should be laid out. Prolonged hospitalisation 
especially in intensive care and burn units complicate antibiotic choices further. 
Healthcare-related BSI episodes can be recurrent and pose daunting challenges.  
6.4.2 KP isolate susceptibility patterns 
It was not possible to report on time to empiric or definitive antibiotic administration 
as healthcare providers documented the infection poorly in the case files. On the other 
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hand, it was possible to equate antibiotics introduced at the time of the definitive 
blood culture as the empiric antibiotic. The empiric antibiotic prescribed in response 
to the BSI was appropriate in 77.1% (307/398) of children, 241/398 (73.5%) children 
with ESBL KP BSI and 66/70 (94.3%) children with non-ESBL KP BSI. Once the 
laboratory results became available, the healthcare providers adjusted the antibiotic 
cover, and this delay did not increase crude mortality p=0.29, RR 0.83 (95% CI: 0.59-
1.16), 87/307 (28.3%) children on appropriate antibiotics died versus 31/91 (34.1%) 
children on inappropriate empiric antibiotics.  
6.4.2.1 KP isolate susceptibility patterns for CA KP BSI 
This analysis showed that at RCWMCH, this combination, ampicillin plus gentamicin, 
would not have provided adequate cover for 28.7% (n/N= 15/21) children with 
possible community-acquired KP BSI. However, a combination of ampicillin plus 
amikacin would have improved cover to 90.5% (n/N= 19/21) of children. The 
antibiotic susceptibility patterns of the KP isolates were analysed in two periods 
2006-2008 and 2009-2011. It was hoped that this would provide some insight into 
the evolution of resistance over the 6 year study period, however the numbers 
included in the present study were small. In the period 2006-2008 antibiotic choices 
of ampicillin with gentamicin, or cefotaxime alone would have provided inferior cover 
for 54.6% (n/N=6/11) and 45.5% (n/N=5/11) KP isolates compared to ampicillin 
plus amikacin, ceftriaxone plus amikacin or ertapenem alone where isolate cover was 
90.9% , 90.9% and 100% respectively. In the period 2009-2011, numbers were again 
small, ampicillin plus gentamicin, ampicillin plus amikacin, ceftriaxone plus amikacin, 
would all have been effective for 90% of isolates and ertapenem would be effective 
for 100% of isolates. The numbers involved were too small to allow any firm 
conclusions.  
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6.4.2.2 KP isolate susceptibility patterns for healthcare-related KP 
BSI 
Analysis of the KP isolates susceptibility patterns over the years 2006-2008 and 
2009-2011 showed that antibiotic regimens containing gentamicin or cefotaxime 
intended for Gram negative cover for healthcare related infections were inferior in 
that <20% of isolates were susceptible, however this was not relevant for RCWMCH. 
Over the two time periods cover provided by amikacin deteriorated from 87.9% 
(n/N=152/173) to 64% (n/N=121/189). Piptazobactam with amikacin combination 
cover for KP isolates dropped from 91.9% (n/N=157/171) to 81.6% (n/N=142/174).  
It was also evident that cover provided by ertapenem was not guaranteed- from 100% 
(n/N=169/169) susceptible in the period 2006-2008 to 98.9% (187/189) in the 
second half of the study period. From these results, in the case of critically ill children 
at RCWMCH, one cannot recommend empiric antibiotic combinations of ceftriaxone 
and amikacin or piptazobactam and amikacin, which were used at RCWMCH for 
empiric cover for presumed HAI during the study period. 
In one study, antibiotic susceptibility of KP across public sector sentinel sites in South 
Africa ranged from 85-98% susceptibility to amikacin, 38-79% for piptazobactam, 20-
29% for gentamicin, 91-100% for ertapenem. Clinical data were not reported in these 
annual reports; however, early signs of carbapenem resistance were becoming 
evident (Perovic et al., 2013). Ertapenem does not provide adequate anti-
pseudomonas activity making empiric antibiotic selection for HAIs a complex issue. 
The likely range of offending organisms should be carefully considered and linked to 
multiple factors.  
The need for prudence is not only driven by fiscal constraints but also by the threat of 
carbapenamase resistance, which has now complicated matters further (Nordmann 
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et al., 2009; Perovic et al., 2013). These include the danger imposed by other multi-
drug resistant hospital-acquired infections. Ariffin et al. reported that carbapenem 
antibiotics were the most effective against ceftazidime-resistant KP BSI in children in 
an oncology unit with febrile neutropaenia if they were given within 48 hours of 
developing the BSI. At the same institution researchers showed that over 8 years the 
resistance trends of KP isolates to ceftazidime and amikacin were very similar and 
ranged between 21 and 55 % resistance, thus limiting their usefulness in critically ill 
children (Ariffin et al., 1999). Kim et al. reported that outcomes were less favourable 
in children with ESBL-producing Gram-negative BSI treated with aminoglycosides 
compared with children who had non-ESBL infections, the bloodstream isolates were 
taken from Korean children hospitalised from 1993-1998. Imipenem was used for 10 
children- 7 had ESBL-producing  Escherichia coli or KP BSI and 3 had non-ESBL Gram-
negative BSI, 2 of the children with ESBL infection did not survive (Kim et al., 2002). 
Currently many units would now favour the effectiveness of a carbapenem antibiotic 
as first-line treatment for a serious KP BSI. 
 
6.5 Objective Five: An evaluation of factors associated with 
inpatient mortality  
6.5.1 Case fatality rate 
KPBSI constitutes a serious medical condition with high mortality; this study revealed 
a case fatality rate of 30% (123/410) children died with 77% (95/123) of deaths 
occurring within 14 days of the definitive blood culture. In published paediatric 
studies of Gram-negative BSI including KP, researchers also documented high 
mortality, ranging from 13 to 36% (Kim et al., 2002; Zaoutis et al., 2005; Velaphi et al., 
2009; Samanta et al., 2009; Bonadio, 1989). The fact that 46% (57/123) of the deaths 
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occurred within 3 days of the blood culture speaks to the rapidity of onset of organ 
failure in patients with KP septicaemia. The deaths occurred anywhere in the interval 
from day the healthcare providers drew KP blood culture to 73 days after. It was 
assumed that deaths occurring within 3 days of the positive blood culture related to 
the BSI. Berkley et al. reported similarly that 70.5% (217/308) deaths in rural Kenyan 
children with bacteraemia occurred within 3 days of positive blood culture (Berkley 
et al., 2005). Consistent with this, 63% (19/30) of neonates’ deaths occurred within 
48 hours of KP BSI (Velaphi et al., 2009). Naidoo et al. reported that 75% of 32 deaths 
occurred within 7 days in children with Staphylococcus aureus BSI at RCWMCH. Marra 
et al. reported on 15-day mortality in nosocomial KP BSI in a study involving adults 
and children in Virginia, USA; in that study 26/108 (24.1%) of the patients died within 
15 days of the blood culture.  
6.5.2 Factors associated with mortality in children with KP BSI 
In the multivariate analysis using generalised linear modelling, the study revealed 
excoriated skin, HIV infection, being in the PICU, or needing PICU admission as 
significant risk factors for death. It also showed that children with KP BSI without 
clinical focus were less likely to die, p value= 0.03: RR 0.71 (95% CI 0.51-0.97). This 
is in comparison with children who had a clinical focus of infection.  
The limited number of published paediatric studies reporting on KP and other Gram-
negative BSI lack multivariate mortality risk factor analyses. Kim et al. identified ESBL 
production 26.7% versus 5.7 %, p=0.001, and the presence of shock on admission in 
40% versus 9.4% in those without shock as significant risk factors for death, p-
value=0.001 (Kim et al., 2002). Velaphi et al., who reported a case fatality rate of 30%, 
found higher mortality of 42% versus 25% in neonates receiving inappropriate 
antibiotics compared with appropriate cover as a risk factor (Velaphi et al., 2009). 
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Ariffin et al., who reported higher mortality in those with appropriate treatment 
delays beyond 48 hours, supported a similar result (Ariffin et al., 1999). In contrast, 
Tsai et al. reported other infectious complications after the onset of BSI and 
pulmonary hypertension as independent risk factors for mortality in neonates with 
Gram-negative, including KP, BSI in Taiwan (Tsai et al., 2014).  
6.5.2.1 Excoriated skin 
The present study finding of excoriated skin as a significant risk factor for mortality 
in a paediatric patient population was novel and has significant clinical importance. 
In the present study, 27 children were admitted with burn wounds. However, there 
were also 130 (32%) children with areas of excoriated skin sufficient to merit 
documentation by the caring nurses and doctors. In this study, excoriated skin 
remained an independent potential risk factor for mortality in the adjusted analysis. 
Other researchers have shown that invasive burn-wound infections are a serious 
complication of paediatric burn patients and contribute significantly to their demise 
(Sheridan, 2005). Multidrug resistant nosocomial Gram-negative bacteria including 
KP have been implicated in the aetiology in resource poor countries (Bhat and 
Vasaiker, 2010; Komolafe et al., 2003).  
There are few published paediatric studies, but one could reasonably speculate that 
the breakdown of the integrity of normal skin barriers under certain circumstances 
could lead to invasive bacterial infections, particularly with enteric colonisers. A 
retrospective paediatric study from RCWMCH, Cape Town involving 112 children 
with meningococcal-associated purpura fulminans found KP and other organisms 
contaminating necrotic wounds (Numanoglu at al., 2007). This finding is relevant to 
developing countries because poor nutrition as well as micronutrient deficiencies 
such as zinc deficiency adversely affected skin integrity (Kumar et al., 2012). The 
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study was not conclusively able to demonstrate increased mortality linked to 
moderate or severe underweight; however, infection is recognized as one of the risk 
factors for mortality in children with acute severe malnutrition (WHO, 2012). Some 
research with newborns has been carried out where maintaining skin barrier 
integrity to reduce infection has shown some success in reducing mortality by 26% 
and 32% in 497 preterm infants. In this study, researchers randomised the infants to 
receive one of two skin emollients versus the control group who did not receive 
emollient care (LeFevre et al., 2010). Broken skin areas may represent significant 
illness in patients exhibiting skin failure as part of a coexisting multiorgan dysfunction 
syndrome (MODS). Poor skin integrity is not amenable to laboratory testing but 
assessed by gross inspection for extent and depth of skin necrosis (Irvine, 1991; 
Langemo and Brown, 2006). 
6.5.2.2 Children in need of PICU support 
Children in need of PICU support are typically critically ill, and it is not surprising that 
mortality in this group of children increases. In this study, children with KP BSI 
experienced a number of organ dysfunctions because of the septicaemic process. 
These dysfunctions included respiratory failure, acute renal and hepatic dysfunction, 
and coagulation disturbances. Mortality increased in children with any of these 
clinical complications combined with KP BSI, p=0.0001. One can predict outcome 
measures including mortality in PICU patients using a validated score known as the 
paediatric logistic organ dysfunction (PELOD) score, which utilises a number of 
physiological and laboratory measures of organ function. As such, any organ 
dysfunction contributes to the PELOD score and can help predict mortality in PICUs 
(Leteurtre et al., 2003). 
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6.5.2.3 The effect of HIV infection 
A separate, dedicated section under the subtitle of Objective 6 includes a thorough 
discussion of the significant effect from HIV infection on the outcome of KP BSI. 
6.6 Objective six: Effect of HIV infection on the outcome of children 
with KP BSI  
Routine testing of all children for HIV infection admitted into the non-surgical wards 
has always been strongly encouraged at RCWMCH. Despite this, in the present study, 
the HIV-status was known in 288 of 410 children (70.2%), the reports showed 20% 
(82) to be HIV-infected. In the present study’s 82 HIV-infected children, diarrhoeal 
disease in 52/82(63.4%) children, and pneumonia in 35/82 (42.7%) were the two 
most common presenting diagnoses. These infectious diagnoses are common 
presenting complaints in HIV-infected children from Sub-Saharan Africa.   Crude 
mortality was higher in HIV-infected children compared with uninfected children (RR 
1.91 (1.40-2.62), p<0.0001)). Of the 82 children known to be HIV-infected, 39 (47.5%) 
children died; 41 (50 %) children were on ART at the time of the KP BSI. The median 
time on ART before the KP BSI was 19 (IQR 8-66) days; even though ART may have 
provided some protection against death (p=0.02; RR 0.56 (CI 0.34-0.92)), the 
mortality of HIV-infected children with KP BSI was high throughout the study period. 
There was 1/ 5 (20%) child who died who had been on ART for 6 months or longer 
compared to 13/36 (36.1%) children who died and had been on ART for less than 6 
months, p= 0.44.  This may reflect the severity of this particular Gram-negative BSI in 
the presence of HIV infection. Early ART has been shown to improve survival and 
immunity in infants (Cotton et al., 2013). There are limited numbers of African 
paediatric studies providing information on the effect of HIV infection on the 
epidemiology KP BSI in hospitalised children, the numbers in the present study were 
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small. The study also revealed that HIV infection linked significantly to ESBL-
producing KP and a higher risk of mortality.  
There is limited information on the association of HIV infection and Gram-negative 
BSIs. In a Kenyan prospective paediatric study, KP ranked second behind Escherichia 
coli in the aetiology of nosocomial Gram-negative BSIs, causing 20% (43/156) of the 
BSI. Healthcare providers performed HIV testing in 27% of admissions, with 2% 
known to be positive. Overall, the case-fatality rate of nosocomial BSI was 53% 
compared with 24% in children with community-acquired BSI. The data did not 
reveal the contribution of HIV infection to mortality (Aiken et al., 2011). HIV-infected 
African children harbour an array of colonising potential pathogens including ESBL-
producing Enterobacteriaceae (Cotton at al., 2008); this places them at risk for 
invasive infections. The South African government introduced a national rollout of 
ART for South African HIV-infected children in 2004, with access progressively 
improving throughout the study period. The present study findings should spur 
continued advocacy for the elimination of paediatric HIV disease in sub-Saharan 
Africa and the continued comprehensive management of all HIV-infected children.  
6.6 Other key findings  
Based on the literature review, this study is probably the first comprehensive analysis 
of Klebsiella pneumoniae BSIs (KPBSI) in hospitalised children at a dedicated 
children’s hospital in sub-Saharan Africa. The study revealed that extended-
spectrum-beta-lactamase-producing KP was an important cause of healthcare-related 
BSI at this children’s hospital. This type of infection was associated with high 
mortality. 
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In a 5-year analysis of routine blood culture results from RCWMCH, 56.6% 
(1679/2969) of all pathogenic isolates cultured were Gram-negative organisms. KP 
(41.8%) and Escherichia (29.1%) were the dominant Enterobacteriaceae isolates. The 
proportion of Enterobacteriaceae infections KP caused declined significantly from 
45.8% in 2008 to 31.7% in 2012 (Lochan et al., 2013). These findings are consistent 
with the present study where the annual incidence rate of KPBSI increased from 2.32 
cases per 1000 hospital admissions per year in 2007 to 3.75 in 2009. This then 
declined to 2.25 in 2011.  
The incidence rates of KP BSIs at RCWMCH have undergone reductions overall with a 
curious surge over 2009 and 2010. The following postulate may have some bearing: 
the South African measles epidemic started in the Gauteng province, spread to the 
Western Cape Province of South Africa in 2009, peaked during the diarrhoeal surge 
season in March and April 2010, and abated in 2011. Of 18 431 national laboratory-
confirmed measles cases, infants were the most severely affected both in terms of 
requiring hospitalisation and in terms of death; HIV-infected children bore the brunt 
of mortality (Ntshoe et al., 2013; le Roux et al., 2012). At the same time, pandemic 
Influenza A H1N1 swept through the country as part of the 2009 global pandemic. 
Both measles and Influenza A H1N1 cause severe respiratory dysfunction as well as 
acute gastroenteritis. The effect of both illnesses was associated with severe pressure 
on beds and subsequent overcrowding in all wards of RCWMCH. These epidemics 
affected every healthcare facility within the province equally. It is possible that viral-
induced lung damage together with the pressure on limited resources and a likely 
breakdown of infection control measures facilitated the spread of all healthcare 
associated infections including KP. Healthcare providers did not provide evidence of 
laboratory molecular PCR testing or lack thereof for genetic relatedness of the 
 127  
nosocomial or healthcare associated isolates. These diagnostic tests are not routine at 
the institution’s NHLS laboratory. 
6.7 Study limitations 
This hospital-based retrospective study had many of the limitations of a retrospective 
review. Sedgwick discussed the merits and shortcomings of retrospective studies 
(Sedgwick, 2014).  
This was a tertiary-hospital-based study. The true burden of community-acquired KP 
BSI may have been underestimated as the other provincial tertiary children’s hospital, 
secondary, or even district hospitals could have admitted and successfully managed 
these children. An estimate of the true burden would require a thorough review of the 
NHLS laboratory databases and collaboration with these paediatric wards outside of 
RCWMCH. 
Hand written patient records provided much of the patient demographic data during 
the study period; this was the norm at RCWMCH. The study children were a 
heterogeneous group of hospitalised infants and children with diverse reasons for 
hospitalisation cared for in different wards throughout the hospital. The recorded 
detail of their clinical progress and temporal sequence of events varied somewhat in 
the different disciplines. For instance, the nursing and clinician notes for children 
within the PICU contained considerably more detail as compared to the notes for 
children in other wards. There was also clinician-to-clinician variation in the medical 
wards as well as in the case of medical notes versus surgical notes. Further, as the 
study was retrospective, it was difficult to determine accurately the exact clinical 
events or even grand round discussions healthcare providers did not record in the 
case notes that triggered the investigations. One example was the fact that not all 
 128  
study children experienced fever at the time of the KP BSI. Horan et al. advocate that 
healthcare providers may consider and report clinical sepsis for CDC surveillance 
purposes in neonates and infants in the absence of fever (Horan et al., 2008). The 
exact timing of the blood cultures at the bedside was almost never recorded in the 
case notes. However, recording at the NHLS laboratory was documented accurately, 
but there may have been delays from drawing of blood culture to receipt at the 
laboratory. The same is true of the exact timing of empiric antibiotic administration. 
This created difficulties in the analysis of treatment delays. In addition, the case notes 
did not contain records of the volumes of blood drawn for blood culture. They almost 
certainly did not conform to consensus guidelines that RCWMCH introduced in 2014 
(Lochan et al., 2014). As such, using very low volumes of blood, less than one millilitre 
as was popularly practised in some cases, may have missed some children with KP 
BSI. This would lead to underestimating the case numbers in both the community-
acquired group as well as the healthcare-related group. 
WHO Integrated Management of Childhood Illness (IMCI) guidelines indicate that 
healthcare providers should consider infants and children less than 5 years old who 
have possible serious infections at primary care level and as such should give 
intramuscular ceftriaxone prior to transfer to their referral centre (DOH SA, WHO, 
UNICEF, 2014). This could also have lead to underestimating at least the non-ESBL KP 
BSI cases.  
The laboratory dataset was incomplete as sensitivities to piptazobactam were not 
available for all isolates, the clinical dataset was also incompletete as individual 
records were missing in some cases. Furthermore, inaccurate note keeping made it 
difficult to verify clinical data or decisions made during grand rounds. Relevant risk 
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factor details may have varied considerably in the records, which is another problem 
with retrospective data collections.  
The definitions used to classify the type of infection into nosocomial, healthcare-
associated, and community-acquired are not the current CDC classifications but an 
older version of what the CDC has cited. Horan et al. reported the CDC’s updated 
definitions replaced the term nosocomial infection with the term healthcare-
associated infection (HAI) and recognised that these HAIs only include those that were 
not present on admission (Horan et al., 2008). Further, the 2013 CDC Protocol 
Clarifications no longer refer to community-acquired infections but rather to present 
on admission (POA) infections such as documented signs and symptoms of infection 
present prior to admission and during the first 48 hours of admission (CDC, 2013). 
According to these definitions, there is no separation between patients residing in 
intermediate healthcare facilities and high-risk individuals harbouring resistant 
hospital-related organisms. Thus, the new definitions would only consider them as 
having POA infections or HAI.  
There has been much said about inconsistencies of such classifications in the 
literature. This includes recognizing that children residing in intermediate healthcare 
facilities require a different definition of BSI acquired within those facilities and have 
infections related to their previous healthcare contact (Henderson et al., 2013). The 
definitions chosen in this study should provide clarity to understanding KP infections 
in children residing in intermediate facilities, a subset belonging to HAIs. This allowed 
an exploration of the antibiotic profile of the KP isolates to see whether BSI infections 
in these children with these specific HRF need different antibiotic cover. The study 
results indicated that the susceptibility patterns of the KP bloodstream isolates of this 
subgroup of children suggest that healthcare providers should regard them as 
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nosocomial. In this study, a created definition combined children with nosocomial KP 
BSI with those with healthcare-associated KP BSI into one group called healthcare-
related KP BSI. Healthcare researchers await further clarity in consensus definitions. 
However, the outcomes of KP BSIs in children living in intermediate facilities are not 
different to children living at home, and they require the same effective therapy. 
Although the study was also limited by the fact that it addressed a single organism, 
the study allowed comparison with a parallel study on Staphylococcus aureus BSI at 
this same study site (Naidoo et al., 2013). Together the studies provide clinically 
relevant information for the appropriate antibiotic treatment of KP and 
Staphylococcal aureus BSIs at RCWMCH. 
 The presence of septic shock was a clinical decision made at the discretion of the 
attending physicians and helped to define the binary for the presence or absence of 
septic shock. Whether these decisions conformed to consensus definitions could not 
be determined in this retrospective study. Further, rectal swabs were not routine in 
children re-admitted within a defined time. As a result, one was unable to use the 
study to speculate further on the role of shock and gut pathogen colonisation in both 
ESBL acquisition and risk of mortality. 
Skin excoriation relied on nurses or doctors’ documentation in their notes rather than 
being defined by a consensus definition. Nevertheless, it is possible that in some cases 
the condition was present but not documented in the case notes; additionally, the 
extent and severity could not be standardised. The terminology used to describe the 
dermatological changes did not follow consensus definitions and could not be verified 
retrospectively. At least one such document exists for the description of skin changes 
and failure in dying patients (Sibbald et al., 2009).  
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What the admitting doctors and any pharmacy prescription sheets available 
documented limited the history and detail of exposure to previous hospitalisation and 
antibiotics. Due to the retrospective design of the study, the study did not capture any 
outpatient exposures and admissions to hospitals other than RCWMCH that the 
RCWMCH folders did not record.  
Despite the established benefit of early ARV therapy in children identified as HIV 
infected and the ready availability of HIV testing at RCWMCH, 122 children had 
unknown HIV statuses. This may have limited fully understanding the effect HIV 
infection had in the epidemiology of KP BSI. This study was also limited to the 
epidemiology of only one member of the Enterobacteriaceae family: KP. As such, the 
bigger picture and the roles of the other Gram-negatives in the aetiology of paediatric 
healthcare associated infections remain unclear. Expanding on this and including 
other healthcare-related bacterial pathogens with the knowledge of their resistance 
patterns would do much to enhance management strategies. This knowledge and 
ranking, together with the clinical detail, would have significant clinical implication. 
The complexity and severity of illnesses that force some children to remain within the 
healthcare environment for prolonged periods may lead to a proportion inevitably 
succumbing to healthcare-related infections. The outcomes of these children depend 
somewhat on the correct treatment choices.  
The risk factors of exposure to ESBL-related BSI as well as those relating to mortality 
found in the study were those of association rather than of proven causation. This is 
inevitable in a retrospective description. However reproducibility of significance of 
pre-hospital treatment with 3rd and or 4th generation cephalosporins in other studies 
suggests that this may be causal. 
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Finally, there may have been referral bias. The information came from only one of 11 
provinces in South Africa: the Western Cape, and from one tertiary hospital. This 
makes generalizability of results difficult.  
6.8 Study strengths 
The study is the first large African study addressing a single important Gram-negative 
organism, KP, in a hospital-based epidemiological study. The study helped to identify 
all children with laboratory confirmed KP BSIs at RCWMCH during the study period 
1st January 2006- 31st December 2011. Only counting the first episode of BSI in the 
cases where healthcare providers took more than one blood culture around the time 
of the bacteraemic event helped to prevent over-representing numbers. 
Further exploration of variables identified by univariate analysis in an adjusted 
analysis helped with identifying associations between ESBL-associated infection and 
mortality. The factors so identified have good clinical relevance in the management of 
sick children.  
The definitions used in the study in categorising the origins of the KP BSIs have 
enabled insight into the antibiotic susceptibility patterns of KP infections acquired by 
children living in intermediate facilities. This should enable appropriate antibiotic 
prescribing in the future. Gleaning the spectrum of risk factors from published 
paediatric reports as well as through years of clinical exposure to sick children gave 
sound clinical pertinence.  
The severity of the implications of HAIs have been realised because of this and other 
analyses at RCWMCH. Therefore, RCWMCH has introduced several specific 
interventions to reduce the risk of nosocomial infections. Active surveillance of 
nosocomial infections occurs at laboratory level with positive blood culture results 
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fed back to clinicians via the Paediatric Infectious Diseases Unit (PIDU). A single part-
time nurse whose responsibilities lie in other areas than hospital infection control has 
run education strategies to reinforce hand washing and wide spread use of 
appropriate hand sanitizers. Management has made standardised guidelines for the 
drawing of blood cultures available throughout the hospital. Management has also 
introduced antibiotic stewardship grand rounds as a necessary strategy not only to 
curb inappropriate antibiotic prescribing but also to optimise patient outcomes. 
There has been some commitment by hospital management to reduce overcrowding 
in all the wards, particularly the short stay wards (SSW), the provision of negative 
pressure ventilation systems, and an increase in the number of isolation cubicles 
available during recent upgrades of two of the general medical wards. These steps 
may well have been partly responsible for the reduction of the incidence of this multi-
drug resistant organism at RCWMCH. On-going surveillance and acceptance of 
recommendations to engage Hospital Managers to set up a dedicated hospital 
infection control unit should provide further evidence of this speculation.  
The study findings may not be generalizable to community settings as the study site 
was a tertiary-hospital-based review. However, some of the lessons about antibiotic 
misuse, poor hygiene, and particularly the poor outcome of children with this form of 
BSI are relevant to all healthcare facilities. 
Finally, the study has largely addressed the stated study objectives, including an 
attempt at addressing the knowledge gap on the lack of African data on an important 
pathogen. 
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CHAPTER SEVEN: CONCLUSION 
7.1 Conclusions 
This study has made an important contribution to the understanding of paediatric KP 
BSI in hospitalised children. It contains a description of the emerging problem of 
multi-drug resistant KP BSIs at RCWMCH. 
 Key messages: 
 KP was an important cause of healthcare-related BSIs in the period 2006-2011. 
 ESBL-production by KP requires careful attention in the consideration of the 
empiric antibiotic regimens that healthcare providers draw up for the different 
illness categories. 
 ESBL-production by KP significantly diminishes the number of affordable 
antibiotic choices. 
 KP BSI was associated with high mortality. 
 Infants and HIV-infected children were vulnerable groups in the setting of 
healthcare infections and had increased mortality. 
 The high prevalence of healthcare-related infections has major implications for 
patient outcome. 
 Healthcare providers should regard KP BSI in children living in intermediate 
healthcare facilities as having the same antibiotic susceptibility patterns as those 
who develop nosocomial KP BSI. 
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7.2 Recommendations 
 There is a need to investigate KP infections in other parts of South Africa as this 
would enable healthcare providers to clarify the underlying risk factors which 
may inform antibiotic and infection control practice.  
 The study findings provide support to all efforts aimed at strengthening infection 
control measures. 
 Antibiotic stewardship is a non-negotiable strategy that healthcare providers 
must accept and is critical at all levels of healthcare facilities. Clear hospital 
antibiotic guidelines for the use of both first-line and second line antibiotics 
should be available to all prescribers. This stewardship lies within the 
collaborative ambit of infectious diseases specialists, pharmacy departments, and 
microbiology departments. 
 Healthcare providers should develop standard operating procedures (SOP) to  
control and prevent hospital acquired infection at ward level including: sterile 
insertion of peripheral venous cannulae, including careful site preparation and 
specified maximum duration of a single peripheral intravenous cannula;  how to 
set up and manage intravenous infusions in a sterile manner and how to manage 
and use multi-dose intravenous medication vials 
 Healthcare providers should pay careful attention to managing areas of broken 
skin in children. 
 HIV-infected children need careful comprehensive management to remain well. 
 Infection control measures are key interventions in reducing the risk of healthcare 
associated infections; therefore, hospitals should commission a dedicated 
infection control unit. 
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 Collaborative reviews of BSIs in children within the province would provide 
meaningful information that could potentially identify targeted interventions.  
 Further efforts to reduce the socioeconomic determinants that bring children into 
healthcare environments must continue if South Africa is to achieve the 
Millennium Development Goals (MDG) 4 targets. 
 A well-designed prospective epidemiological study looking at all the 
Enterobacteriaceae with a detailed analysis of strain identification and rigorous 
clinical data correlation may provide further insight into a complex but important 
paediatric problem. This, however, would require considerable resource 
allocation. 
7.3 Summary of what can be done 
Many challenges exist in the prevention of nosocomial sepsis including how to reduce 
overcrowding, enforce infection control measures and strict antibiotic stewardship, 
and deal with careless antibiotic use by healthcare professionals (Hague, 2011). 
Healthcare providers should curtail indiscriminate use of 3rd generation 
cephalosporins and should continue to enforce strict approval protocols for 
prescribing carbapenem antibiotics. Good hand hygiene practice is a fundamentally 
simple and effective way to help contain the problem of nosocomial infections even in 
the face of overcrowding. Cohorting and isolating patients carrying drug resistant 
organisms would also provide some protection to other hospitalised children against 
the spread of infection. Another improvement would be improved staff training on 
the aseptic handling of all procedures pertaining to intravenous infusions. Admission 
rectal swabs on all children that have been previously hospitalised, up to 12 months, 
may allow better infection control practices. This public children’s hospital needs a 
regular re-evaluation of the prevalence of nosocomial sepsis after implementing 
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aggressive preventative interventions. Microbiologic characterisation plays an 
important role in identifying children at risk and guiding therapy. Improved 
techniques, if available and affordable, for rapid and accurate identification of 
resistant isolates are also important.  
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APPENDICES 
Appendix A: Data collection sheet 
Study title: Klebsiella pneumoniae bloodstream infections in hospitalised children at Red 




Date of birth 
Gender MALE FEMALE 
Admission mass (kg) Z-score:
Admission status 
Date of admission to hospital 
First ward location 
Initial diagnosis 
Subsequent ward movements before diagnosing K. pneumoniae bloodstream infection
Ward Date of admission 
Past admission history 
Admission during preceding 28 days YES NO UNKNOWN 
Admission during preceding 1 year YES NO UNKNOWN 
Number of admissions in preceding year 
Details of most recent admission 
Date of admission 
Principal diagnosis 
Duration of admission 
Antibiotic exposure during admission within last year 
Exposure to 3rd generation cephalosporins YES NO 
Generic name of drug Period of exposure(dates) 
Exposure to 2rd generation cephalosporins YES NO 
Generic name of drug Period of exposure(dates) 
Exposure to fluoroquinolones YES NO 
Generic name of drug Period of exposure (dates): 
Exposure to macrolides YES NO 
Generic name of drug Period of exposure (dates): 
Exposure to Cotrimoxazole YES NO 
Generic name of drug Period of exposure (dates): 
Exposure to carbapenems Yes No 
Generic name of drug Period of exposure (dates): 
Exposure to aminoglycosides Yes No 
Generic name of drug Period of exposure (dates): 
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Exposure to Piptazobactam Yes No 
Generic name of drug Period of exposure (dates): 
HIV infection 
Patient tested for HIV YES NO UNKNO
WN 
HIV Test Date Result 
Rapid 
HIV ELISA 
HIV DNA PCR 
HIV status exposed infected uninfected UNKNO
WN 
CD4 completed YES NO UNKNOWN 
CD4 date 
CD4 absolute count CD4 percentage 
On ART at time of infection YES NO UNKNOWN 
Date of starting ART Time on ART (days/months) 
Potential risk factors 
Resident in long term health facility YES NO 
Permanent indwelling catheters / tracheostomy YES NO 
Date of Insertion 
Date of removal: (if applicable) 
Current admission (before diagnosing bloodstream infection):- 
Intravenous canula / access YES NO 
Intraosseous access YES NO 
Central intravenous catheter YES NO 
IV fluid administration YES NO 
Duration of IV fluids before bloodstream infection 
(days): 
Naso- / Endo-tracheal intubation YES NO 
Tracheostomy YES NO 
Urinary Catheter YES NO 
Surgery during admission YES NO 
Procedure type 
Excoriated skin YES NO 
K pneumoniae isolation within last year YES NO 
Date of K pneumoniae isolation
Other 
Underlying medical condition 
Chronic lung disease YES NO 
Chronic renal failure YES NO 
Immunosuppressive therapy YES NO 
Long-term glucocorticosteroid administration 
(>1mo) 
YES NO 
Congenital syndrome (specify) YES NO 
Other YES NO 
Specify 




K pneumoniae bloodstream infection 
Date of blood culture:  
Classification:- Nosocomial 
Community-acquired Institution-associated community acquired 
Evidence supportive of invasive infection:- 
Fever > 38C Clinical diagnosis of invasive infection 
Clinical focus of infection Elevated C-reactive protein 
Elevated white cell count Low white cell count 
Other (specify):  
Focus of infection 
Primary bloodstream infection Catheter-related bloodstream infection 
Pneumonia Urinary tract infection 
Meningitis Soft tissue infection 
Septic arthritis Osteomyelitis 
Other (specify):  
 
Investigations at time or close to bacteraemic event 
Full blood count:- 
Haemoglobin                                      g/dL 
MCV                                      fL 
White blood count                                      x109/L 
Neutrophil count                                      x109/L 
Lymphocyte count                                      x109/L 
Platelet count                                      x109/L 
C-reactive protein /      PCT                      mg/L                       µg/L                    
 
Antibiotic sensitivity of cultured organism 
Ampicillin S I R N/S 
Cotrimoxazole S I R N/S 
Co-Amoxiclav S I R N/S 
Erythromycin S I R N/S 
Gentamicin S I R N/S 
Amikacin S I R N/S 
Ceftriaxone / cefotaxime S I R N/S 
Ceftazidime S I R N/S 
Cefepime S I R N/S 
Ciprofloxacin S I R N/S 
Piptazobactam S I R N/S 
Imipenem S I R N/S 
Meropenem S I R N/S 
Ertapenem S I R N/S 
Colistin S I R N/S 
Tobramycin S I R N/S 
Chloramphenicol S I R N/S 
Nalidixic acid S I R N/S 
Nitrofurantoin S I R N/S 
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Other (specify) S I R N/S 
Antibiotic administration: 1. Antibiotics prior to the blood culture 
2. Empiric and definitive antibiotics in response to bloodstream infection
Antibiotics given? YES NO 
Complications and outcome 
Complication associated with bloodstream infection:- 
Septic shock DIC 
Respiratory failure Renal failure 
Hepatic dysfunction Other (specify): 
ICU admission required Yes No Patient In ICU 
Indication for ICU admission: 
Total length of hospital admission: 
Hospital outcome Discharged Died 
Date of discharge / death: 
Cause of death: 
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Appendix C: Protocol amendment Pg1 
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Appendix C: Protocol Amendment Pg2 
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Appendix D: Annual progress report 
Signature removed
Signature removed
Signature removed
